<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533612444539</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533612444539</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Role of B Vitamins in the Management of Heart Failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Azizi-Namini</surname><given-names>Parastoo</given-names></name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff1-0884533612444539">1</xref>
<xref ref-type="aff" rid="aff3-0884533612444539">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ahmed</surname><given-names>Mavra</given-names></name>
<degrees>BSc (Hons)</degrees>
<xref ref-type="aff" rid="aff1-0884533612444539">1</xref>
<xref ref-type="aff" rid="aff3-0884533612444539">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yan</surname><given-names>Andrew T.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533612444539">1</xref>
<xref ref-type="aff" rid="aff2-0884533612444539">2</xref>
<xref ref-type="aff" rid="aff4-0884533612444539">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Keith</surname><given-names>Mary</given-names></name>
<degrees>PhD, RD</degrees>
<xref ref-type="aff" rid="aff1-0884533612444539">1</xref>
<xref ref-type="aff" rid="aff3-0884533612444539">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0884533612444539"><label>1</label>Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, Canada</aff>
<aff id="aff2-0884533612444539"><label>2</label>Division of Cardiology, St Michael’s Hospital, Toronto, Ontario, Canada</aff>
<aff id="aff3-0884533612444539"><label>3</label>Department of Nutritional Sciences, Toronto, Ontario, Canada</aff>
<aff id="aff4-0884533612444539"><label>4</label>Department of Medicine, University of Toronto, Toronto, Ontario, Canada</aff>
<author-notes>
<corresp id="corresp1-0884533612444539">Dr Mary Keith, Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, 209 Victoria Street, 5th Floor, Student Centre - Suite 588, Toronto, Ontario, Canada, M5B1T8; e-mail: <email>keithm@smh.ca</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>3</issue>
<issue-title>Cardiovascular and Critical Illness</issue-title>
<fpage>363</fpage>
<lpage>374</lpage>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>Heart failure (HF) is the leading cause of morbidity and mortality in industrialized countries, creating a significant burden on both the healthcare system and quality of life. Research efforts continue to explore new pharmaceutical or surgically based approaches to HF management, but the role of nutrition as an adjunct therapy has been largely ignored. Elderly age, anorexia, malabsorption, premature satiety, and disease severity are among the factors identified as contributing to reduced nutrient intakes in patients with HF. These factors suggest that patients with HF are at increased risk of multiple-nutrient deficiencies, including B vitamins. B vitamins may be of particular therapeutic interest because of their key roles as cofactors in energy-producing pathways. Recently, impaired stores of high-energy compounds have been linked with myocardial dysfunction and prognosis in patients with HF. Therefore, deficiencies of B vitamins might contribute to reduced energy stores and disease progression. This review summarizes the existing literature both with respect to the prevalence of B vitamin deficiency as well as evidence from supplementation trials in patients with HF. The findings suggest that most of the literature in this area has focused on thiamin deficiency in patients with HF, whereas other B vitamins remain largely unstudied. Although few sporadic trials suggest a role for B vitamins in the management of HF, none are conclusive. Therefore, there is a need for larger, more robust trials to assist in defining the B vitamin requirements as well as the impact of supplementation on both morbidity and mortality in patients with HF.</p>
</abstract>
<kwd-group>
<kwd>heart failure</kwd>
<kwd>vitamin B complex</kwd>
<kwd>vitamin B deficiency</kwd>
<kwd>thiamine</kwd>
<kwd>riboflavin</kwd>
<kwd>niacin</kwd>
<kwd>pantothenic acid</kwd>
<kwd>biotin</kwd>
<kwd>folic acid</kwd>
<kwd>vitamin B<sub>6</sub></kwd>
<kwd>vitamin B<sub>12</sub></kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Heart failure (HF) is the leading cause of morbidity and mortality in industrialized countries.<sup><xref ref-type="bibr" rid="bibr1-0884533612444539">1</xref></sup> Anorexia, malnutrition, elderly age, frequent hospitalizations, premature satiety, and disease severity are among the factors identified as contributing to reduced dietary intake and subsequently increased risk of nutrient deficiency in patients with HF.<sup><xref ref-type="bibr" rid="bibr2-0884533612444539">2</xref><xref ref-type="bibr" rid="bibr3-0884533612444539"/><xref ref-type="bibr" rid="bibr4-0884533612444539"/><xref ref-type="bibr" rid="bibr5-0884533612444539"/><xref ref-type="bibr" rid="bibr6-0884533612444539"/><xref ref-type="bibr" rid="bibr7-0884533612444539"/>-<xref ref-type="bibr" rid="bibr8-0884533612444539">8</xref></sup> Furthermore, diuretics are routinely prescribed to patients with HF to manage fluid overload.<sup><xref ref-type="bibr" rid="bibr9-0884533612444539">9</xref></sup> However, these medications are linked with increased urinary losses of electrolytes and micronutrients, potentially contributing to the development of nutrient deficiencies in this population.<sup><xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref><xref ref-type="bibr" rid="bibr11-0884533612444539"/>-<xref ref-type="bibr" rid="bibr12-0884533612444539">12</xref></sup> Dietary factors may play a role in disease outcomes in patients with HF; however, there are few investigations of the micronutrient status of patients with HF.<sup><xref ref-type="bibr" rid="bibr13-0884533612444539">13</xref>,<xref ref-type="bibr" rid="bibr14-0884533612444539">14</xref></sup> Several studies have demonstrated widespread micronutrient deficiency, including B vitamins, in patients with HF.<sup><xref ref-type="bibr" rid="bibr5-0884533612444539">5</xref>,<xref ref-type="bibr" rid="bibr6-0884533612444539">6</xref>,<xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref>,<xref ref-type="bibr" rid="bibr15-0884533612444539">15</xref><xref ref-type="bibr" rid="bibr16-0884533612444539"/><xref ref-type="bibr" rid="bibr17-0884533612444539"/><xref ref-type="bibr" rid="bibr18-0884533612444539"/><xref ref-type="bibr" rid="bibr19-0884533612444539"/>-<xref ref-type="bibr" rid="bibr20-0884533612444539">20</xref></sup> Because the majority of B vitamins act as cofactors in the production of cellular energy,<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> a deficiency of one or more of these vitamins could contribute to the depletion of energy reserves observed in the failing heart.<sup><xref ref-type="bibr" rid="bibr6-0884533612444539">6</xref></sup></p>
<p>Despite advances in therapeutic approaches to the management of HF, this disease continues to remain a costly and burdensome condition on both patients as well as on the healthcare system.<sup><xref ref-type="bibr" rid="bibr22-0884533612444539">22</xref></sup> Moreover, most drug regimens are associated with side effects and have limited safety and efficacy.<sup><xref ref-type="bibr" rid="bibr23-0884533612444539">23</xref>,<xref ref-type="bibr" rid="bibr24-0884533612444539">24</xref></sup> Because nutrient supplementation represents a potentially cost-effective and readily available adjunct therapy, it is important to understand the link between micronutrient status and disease pathogenesis and treatment. Therefore, the aim of this review is to summarize the existing literature regarding the B vitamin status of patients with HF as well as any studies exploring the potential benefits of supplementation in the management of HF.</p>
<sec id="section1-0884533612444539">
<title>Heart Failure: Definition, Etiology, and Risk Factors</title>
<p>According to the World Health Organization, cardiovascular disease is the number one cause of death globally, representing 30% of the total deaths in 2008.<sup><xref ref-type="bibr" rid="bibr25-0884533612444539">25</xref></sup> Current estimates suggest that approximately 5.8 million people in the United States have HF with an incidence of 670,000 new cases identified each year.<sup><xref ref-type="bibr" rid="bibr26-0884533612444539">26</xref></sup> Data from the European Society of Cardiology estimates that half of the patients with a diagnosis of HF will die within 4 years, and in patients with severe HF, 50% will die within 1 year.<sup><xref ref-type="bibr" rid="bibr27-0884533612444539">27</xref></sup> In 2010 alone, the cost of HF in the United States, including healthcare service and medication, reached $39.2 billion.<sup><xref ref-type="bibr" rid="bibr26-0884533612444539">26</xref></sup></p>
<p>HF is a complex clinical syndrome, in which the circulatory function of the heart is insufficient to meet metabolic needs of the body.<sup><xref ref-type="bibr" rid="bibr9-0884533612444539">9</xref></sup> Potential etiologies of HF include ischemic heart disease, dilated cardiomyopathy, valvular disease, hypertension, and congenital heart disease.<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref></sup> Left ventricular ejection fraction (LVEF)<sup><xref ref-type="bibr" rid="bibr29-0884533612444539">29</xref></sup> and the New York Heart Association (NYHA) functional classification are most widely used for assessing HF severity.<sup><xref ref-type="bibr" rid="bibr9-0884533612444539">9</xref></sup> However, because of the lack of correlation between disease severity and LVEF as well as the subjective nature of the NYHA functional classification, biomarkers—specifically brain natriuretic peptide—are being used as indicators of cardiac function.<sup><xref ref-type="bibr" rid="bibr9-0884533612444539">9</xref></sup> The Framingham criteria are mostly used in epidemiological studies to ascertain HF. According to the modified Framingham clinical criteria,<sup><xref ref-type="bibr" rid="bibr30-0884533612444539">30</xref></sup> an individual should have at least 2 major or 1 major and 2 minor clinical factors to be identified as having HF (<xref ref-type="table" rid="table1-0884533612444539">Table 1</xref>).</p>
<table-wrap id="table1-0884533612444539" position="float">
<label>Table 1.</label>
<caption>
<p>Diagnostic Criteria for Diagnosis of Heart Failure<sup><xref ref-type="bibr" rid="bibr30-0884533612444539">30</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0884533612444539" xlink:href="10.1177_0884533612444539-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Major Criteria</th>
<th align="center">Minor Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paroxysmal nocturnal dyspnea</td>
<td>Peripheral edema</td>
</tr>
<tr>
<td>Orthopnea</td>
<td>Night cough</td>
</tr>
<tr>
<td>Elevated JVP</td>
<td>Dyspnea</td>
</tr>
<tr>
<td>Pulmonary rales</td>
<td>Hepatomegaly</td>
</tr>
<tr>
<td>Third heart sound</td>
<td>Pleural effusion</td>
</tr>
<tr>
<td>Cardiomegaly on CXR</td>
<td>Heart rate &gt;120 bmp</td>
</tr>
<tr>
<td>Pulmonary edema on CXR</td>
<td>Weight loss ≥4.5 kg</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533612444539">
<p>CXR, chest radiograph; JVP, jugular venous pressure.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Risk factors for HF include hypertension, diabetes mellitus, obesity, renal failure, anemia, excessive alcohol intake, thyroid dysfunction,<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref></sup> and family history of dilated cardiomyopathy.<sup><xref ref-type="bibr" rid="bibr9-0884533612444539">9</xref></sup> Elevated plasma total homocysteine (tHcy) levels have also been recently suggested as a risk factor for HF.<sup><xref ref-type="bibr" rid="bibr31-0884533612444539">31</xref>,<xref ref-type="bibr" rid="bibr32-0884533612444539">32</xref></sup> One study of 987 patients with HF found that tHcy levels increased significantly with increasing NYHA functional class (<italic>P</italic> &lt; .001) and were negatively correlated with LVEF (<italic>r</italic> = −0.150, <italic>P</italic> &lt; .001).<sup><xref ref-type="bibr" rid="bibr33-0884533612444539">33</xref></sup> Data from the Framingham study also found a strong relationship between plasma tHcy levels and the risk of a future diagnosis of HF in healthy individuals without prior myocardial infarction.<sup><xref ref-type="bibr" rid="bibr32-0884533612444539">32</xref></sup> Although previous studies indicate a link between tHcy and HF severity, the underlying mechanistic role of homocysteine in the development of myocardial contractile failure as well as cardiac remodeling is largely unknown.<sup><xref ref-type="bibr" rid="bibr31-0884533612444539">31</xref></sup> Recently, it has been suggested that elevated serum levels of homocysteine may be a marker of poor prognosis in patients with HF because of its relationship with increased cytokine production.<sup><xref ref-type="bibr" rid="bibr34-0884533612444539">34</xref></sup> Finally, elevated homocysteine may influence the progression of HF by contributing to a higher level of oxidative stress.<sup><xref ref-type="bibr" rid="bibr35-0884533612444539">35</xref>,<xref ref-type="bibr" rid="bibr36-0884533612444539">36</xref></sup></p>
</sec>
<sec id="section2-0884533612444539">
<title>The Role of B Vitamins in the Management of Heart Failure</title>
<p>Common management strategies for individuals with HF include medical therapy, patient education, and cardiac interventional and surgical treatments.<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref></sup> Nutrition recommendations are largely focused on sodium and fluid restriction as well as lipid modification. However, a comprehensive nutrition assessment is rarely conducted as part of the management of these patients.<sup><xref ref-type="bibr" rid="bibr37-0884533612444539">37</xref></sup> It has been suggested that as many as 68% of individuals with HF suffer from malnutrition.<sup><xref ref-type="bibr" rid="bibr2-0884533612444539">2</xref></sup> Loss of body weight has also been linked to a loss of cardiac mass.<sup><xref ref-type="bibr" rid="bibr38-0884533612444539">38</xref></sup> Anorexia,<sup><xref ref-type="bibr" rid="bibr2-0884533612444539">2</xref>,<xref ref-type="bibr" rid="bibr39-0884533612444539">39</xref></sup> increased resting metabolic rate, and hypercatabolism<sup><xref ref-type="bibr" rid="bibr40-0884533612444539">40</xref>,<xref ref-type="bibr" rid="bibr41-0884533612444539">41</xref></sup> are among the underlying reasons for the increased prevalence of malnutrition in patients with HF.<sup><xref ref-type="bibr" rid="bibr42-0884533612444539">42</xref></sup> Furthermore, the recommended dietary allowances (RDA),<sup><xref ref-type="bibr" rid="bibr43-0884533612444539">43</xref></sup> established for healthy individuals,<sup><xref ref-type="bibr" rid="bibr44-0884533612444539">44</xref>,<xref ref-type="bibr" rid="bibr45-0884533612444539">45</xref></sup> may not address the dietary requirements of patients with HF.<sup><xref ref-type="bibr" rid="bibr46-0884533612444539">46</xref></sup></p>
<p>The family of B vitamins includes thiamin (vitamin B<sub>1</sub>), riboflavin (vitamin B<sub>2</sub>), niacin (vitamin B<sub>3</sub>), vitamin B<sub>6</sub> (pyridoxine), folate (folic acid), vitamin B<sub>12</sub> (cobalamin), pantothenic acid, and biotin.<sup><xref ref-type="bibr" rid="bibr47-0884533612444539">47</xref></sup> These water-soluble vitamins play critical roles in the body as coenzymes in energy-producing reactions, including the Krebs cycle.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> Research investigating the relationship between adenosine triphosphate (ATP) synthesis and LVEF suggest that a lower rate of ATP production together with an impaired energy state of the myocardium may increase the risk of HF, in part because of the limited energy stores available for myocyte contraction.<sup><xref ref-type="bibr" rid="bibr48-0884533612444539">48</xref>,<xref ref-type="bibr" rid="bibr49-0884533612444539">49</xref></sup> Therefore, it is logical to hypothesize that having a deficiency of one or more B vitamins may impair ATP production and subsequently contribute to myocardial dysfunction.<sup><xref ref-type="bibr" rid="bibr50-0884533612444539">50</xref></sup> Moreover, the influence of diuretic therapy, dietary intake, and degree of HF severity may adversely affect B vitamin status. Therefore, there is a need to better understand the role B vitamins play in the development, progression, and management of HF.</p>
<sec id="section3-0884533612444539">
<title>Thiamin (Vitamin B<sub>1</sub>)</title>
<p>Thiamin, vitamin B<sub>1</sub> or aneurin, is the most extensively studied B vitamin because of its potential role in the management of HF. The majority of absorbed thiamin combines with ATP in the body to form thiamin pyrophosphate (TPP), which acts as a coenzyme in carbohydrate metabolism.<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref>,<xref ref-type="bibr" rid="bibr47-0884533612444539">47</xref></sup> Classic thiamin deficiency or beriberi is rare and is most often associated with alcoholism in developed countries.<sup><xref ref-type="bibr" rid="bibr51-0884533612444539">51</xref></sup> The clinical signs of beriberi include lesions of the central and peripheral nervous system (dry beriberi) or peripheral vasodilation, edema, tachycardia, and HF (wet beriberi).<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref>,<xref ref-type="bibr" rid="bibr52-0884533612444539">52</xref></sup></p>
<p>Furthermore, malnutrition,<sup><xref ref-type="bibr" rid="bibr18-0884533612444539">18</xref>,<xref ref-type="bibr" rid="bibr39-0884533612444539">39</xref></sup> advanced age,<sup><xref ref-type="bibr" rid="bibr53-0884533612444539">53</xref>,<xref ref-type="bibr" rid="bibr54-0884533612444539">54</xref></sup> frequent hospitalization,<sup><xref ref-type="bibr" rid="bibr5-0884533612444539">5</xref>,<xref ref-type="bibr" rid="bibr54-0884533612444539">54</xref>,<xref ref-type="bibr" rid="bibr55-0884533612444539">55</xref></sup> and use of diuretic medications<sup><xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref>,<xref ref-type="bibr" rid="bibr56-0884533612444539">56</xref></sup> have all been shown to increase the risk of thiamin deficiency in patients with HF.<sup><xref ref-type="bibr" rid="bibr50-0884533612444539"/></sup></p>
<p>Several studies have investigated the prevalence of thiamin deficiency in patients with HF. In the light of current evidence linking impaired energy reserves with the progression of HF together with the key role of thiamin in several energy- producing reactions,<sup><xref ref-type="bibr" rid="bibr47-0884533612444539">47</xref><xref ref-type="bibr" rid="bibr48-0884533612444539"/>-<xref ref-type="bibr" rid="bibr49-0884533612444539">49</xref></sup> it is possible that thiamin deficiency, by limiting the rate of ATP production, might contribute to myocardial dysfunction.<sup><xref ref-type="bibr" rid="bibr50-0884533612444539">50</xref></sup> The reported prevalence of thiamin deficiency ranges from 13% -96% in hospitalized populations and mixed groups of outpatients and inpatients.<sup><xref ref-type="bibr" rid="bibr5-0884533612444539">5</xref>,<xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref>,<xref ref-type="bibr" rid="bibr12-0884533612444539">12</xref>,<xref ref-type="bibr" rid="bibr18-0884533612444539">18</xref>,<xref ref-type="bibr" rid="bibr20-0884533612444539">20</xref>,<xref ref-type="bibr" rid="bibr57-0884533612444539">57</xref>,<xref ref-type="bibr" rid="bibr58-0884533612444539">58</xref></sup> Only 1 study focused on outpatients with HF exclusively and reported a prevalence of thiamin deficiency that was very low (3%; n = 38).<sup><xref ref-type="bibr" rid="bibr59-0884533612444539">59</xref></sup> Case control studies reported a higher prevalence of thiamin deficiency in patients with HF compared with a non-HF control population.<sup><xref ref-type="bibr" rid="bibr5-0884533612444539">5</xref>,<xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref></sup> In addition, a positive correlation between erythrocyte TPP concentration and LVEF was seen in some trials.<sup><xref ref-type="bibr" rid="bibr5-0884533612444539">5</xref>,<xref ref-type="bibr" rid="bibr20-0884533612444539">20</xref></sup> However, it is still difficult to draw any conclusions on the prevalence rate of thiamin deficiency based on the available data because of the inconsistencies in study design and differences in the characteristics of each HF population. Furthermore, variations in the underlying nutrition status of the participants, the dose and type of diuretic medications used, the severity of HF, age range, and the measurement technique used for the assessment of thiamin status<sup><xref ref-type="bibr" rid="bibr50-0884533612444539">50</xref>,<xref ref-type="bibr" rid="bibr60-0884533612444539">60</xref></sup> contribute to the variability observed between studies.</p>
<p>A number of studies have evaluated the status of multiple micronutrients, including B vitamins, in patients with HF. In a study by Gorelik et al,<sup><xref ref-type="bibr" rid="bibr15-0884533612444539">15</xref></sup> the dietary intake of various micronutrients, including thiamin, riboflavin, niacin, and folic acid, was evaluated in 57 elderly (mean [SD] age 74.4 [8.8] years) hospitalized patients with HF who received furosemide at a dose ranging from 40–80 mg/d. The estimated dietary intake of several micro- and macronutrients was compared with those of 40 age-matched ambulatory patients with HF using a 6-month food frequency recall questionnaire. The potential effect of HF severity on nutrient intake was also examined by comparing the level of intake between patients with moderate HF symptoms (NYHA functional class II, n = 37) with those with severe symptoms (NYHA functional class III/IV, n = 20). Thiamin levels were found to be below the RDA in both the HF and control populations, with no difference in the prevalence of thiamin deficiency between the groups. Similarly, no difference in the mean dietary intake of thiamin was found between patients with severe HF compared with those with moderate HF. Therefore, the authors suggested that it was not the presence or severity of HF but other factors, including the use of diuretic medications, that contributed to the development of thiamin deficiency.</p>
<p>In a similar study,<sup><xref ref-type="bibr" rid="bibr61-0884533612444539">61</xref></sup> the intake of macro- and micronutrients, including thiamin, riboflavin, niacin, and folate, was compared between 62 hospitalized patients with HF (mean [SD] age 73.8 [8.9] years; NYHA III/IV) and 62 age- and sex-matched ambulatory patients without HF who attended a geriatric facility. Nutrition data were obtained from the European Prospective Investigation Into Cancer and Nutrition questionnaire. Thiamin intake levels did not differ between the 2 groups, although more than 80% of patients in both groups did not meet the RDA for thiamin. These results, however, may not be generalizable to the entire HF population as a whole because patients with comorbidities (such as those with cachexia, diastolic HF, and renal failure) were excluded from the study.</p>
<p>In a more recent prospective cross-sectional study,<sup><xref ref-type="bibr" rid="bibr17-0884533612444539">17</xref></sup> dietary intakes of several vitamins and minerals were evaluated in 123 stable patients with HF, and the results were compared with 58 control patients without HF. Two sets of 3-day food records (6–10 weeks apart) were used to evaluate dietary intake. The intake of thiamin as well as the proportion of patients not meeting the dietary reference intakes (DRI) for thiamin was similar between the patients with HF and the controls. One of the strengths of this study, compared with the previous 2 studies,<sup><xref ref-type="bibr" rid="bibr15-0884533612444539">15</xref>,<xref ref-type="bibr" rid="bibr61-0884533612444539">61</xref></sup> was the use of a food record to collect intake data, which is considered the gold standard for the assessment of nutrient intake.<sup><xref ref-type="bibr" rid="bibr62-0884533612444539">62</xref></sup> Yet, because the control group was significantly older and had a lower body mass index (BMI) compared with the HF population (<italic>P</italic> = .024 and <italic>P</italic> = .02, respectively), the results of the nutrient intake comparison between the 2 groups may not be comparable.</p>
<p>Previous thiamin supplementation trials in patients with HF have reported significant improvements in cardiac function as well as in thiamin status in response to thiamin therapy.<sup><xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref>,<xref ref-type="bibr" rid="bibr11-0884533612444539">11</xref>,<xref ref-type="bibr" rid="bibr63-0884533612444539">63</xref></sup> One of the first supplementation trials was conducted by Freye and Hartung,<sup><xref ref-type="bibr" rid="bibr63-0884533612444539">63</xref></sup> who administered 50 mg/kg of intravenous (IV) thiamin to 6 hospitalized patients with cardiac or pulmonary insufficiency. The authors proposed that thiamin might function as a mild peripheral vasodilator, thereby contributing to the observed improvement in cardiac performance. In a study by Seligmann et al,<sup><xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref></sup> 6 patients with thiamin deficiency (identified during a prevalence study) were given IV injections of thiamin (100 mg) twice daily for 1 week.<sup><xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref></sup> At the end of the intervention period, the erythrocyte thiamin levels returned to the normal range in all 6 subjects. In addition, LVEF improved in 4 of 5 patients.<sup><xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref></sup> Both of these studies,<sup><xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref>,<xref ref-type="bibr" rid="bibr63-0884533612444539">63</xref></sup> however, were limited by their small sample size. In a follow-up study by Shimon et al,<sup><xref ref-type="bibr" rid="bibr11-0884533612444539">11</xref></sup> 30 patients with HF were randomized to receive either 200 mg/d of IV thiamin or a placebo for 1 week. After 7 days, they observed a significant improvement in LVEF in the supplemented group in comparison with the placebo group (<italic>P</italic> &lt; .05). Subsequently, all patients received 200 mg of oral thiamin supplementation for an additional 6 weeks. At this time, cardiac output improved by 22% (<italic>P</italic> &lt; .01). The erythrocyte thiamin status and NYHA functional class also improved significantly compared with baseline (<italic>P</italic> &lt; .001 and <italic>P</italic> &lt; .01, respectively). In this study, however, the randomization was abandoned after only 7 days of treatment with thiamin. Despite this, the authors concluded that thiamin supplementation could enhance LVEF in patients with HF.</p>
</sec>
<sec id="section4-0884533612444539">
<title>Riboflavin (Vitamin B<sub>2</sub>)</title>
<p>Vitamin B<sub>2</sub> is also commonly known as riboflavin.<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref></sup> Flavin-adenine dinucleotide (FAD) and flavin mononucleotide (FMN) are among the most biologically active forms of vitamin B<sub>2</sub>. Riboflavin acts as a coenzyme in a number of energy- producing reactions and is central to the metabolism of proteins and glucose.<sup><xref ref-type="bibr" rid="bibr44-0884533612444539">44</xref></sup> In a review article on the functions of riboflavin, vitamin B<sub>2</sub> was suggested to act as one of the required factors for homocysteine metabolism.<sup><xref ref-type="bibr" rid="bibr64-0884533612444539">64</xref></sup> Inadequate intake and malabsorption are the primary causes of vitamin B<sub>2</sub> deficiency, which is characterized by cheilosis, dermatitis, peripheral neuropathy, and burning and itching eyes.<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref>,<xref ref-type="bibr" rid="bibr44-0884533612444539">44</xref>,<xref ref-type="bibr" rid="bibr64-0884533612444539">64</xref></sup></p>
<p>To our knowledge, no clinical study has looked exclusively at the relationship between riboflavin deficiency and HF. A number of cross-sectional studies have studied the intake of riboflavin, along with other nutrients, in patients with HF. In a study by Keith et al,<sup><xref ref-type="bibr" rid="bibr6-0884533612444539">6</xref></sup> erythrocyte B<sub>2</sub> levels and plasma B<sub>6</sub> levels were measured in 100 hospitalized patients with HF and were compared with levels in 50 age- and sex-matched volunteers without HF. The dietary intake of thiamin was assessed using a modified semi-quantitative food frequency questionnaire (sqFFQ). The prevalence rate of B<sub>2</sub> deficiency was significantly higher in patients with HF (27%) compared with volunteers without HF (2.2%) (<italic>P</italic> &lt; .001). Interestingly, although the rate of B<sub>2</sub> deficiency was reduced by 17.6% in HF supplement users (either multivitamin or B complex), the prevalence of B<sub>2</sub> deficiency was not significantly different from those who did not use supplements. As a result, the authors suggested that the use of commonly consumed B vitamin supplements might be insufficient to prevent deficiency in patients with HF. Furthermore, the authors reported that 88% of patients with HF had vitamin B<sub>2</sub> intakes that exceeded the estimated average requirement (EAR) cutoff but still had biochemical evidence of B<sub>2</sub> deficiency. Finally, no relationships were reported between vitamin B<sub>2</sub> deficiency and LVEF, presence of malnutrition, or diuretic use.</p>
<p>In a study by Gorelik et al,<sup><xref ref-type="bibr" rid="bibr15-0884533612444539">15</xref></sup> dietary levels of riboflavin were found to be below the RDA in both HF and control groups. It was suggested that the consumption of a Mediterranean diet, older age, or the presence of chronic conditions might have influenced the dietary intake of riboflavin. However, no differences in dietary intake were found between the patients with HF compared with a group of healthy controls or those with moderate or severe symptoms. Similar to the results of Gorelik et al,<sup><xref ref-type="bibr" rid="bibr15-0884533612444539">15</xref></sup> Arcand et al<sup><xref ref-type="bibr" rid="bibr17-0884533612444539">17</xref></sup> did not identify any difference in riboflavin intakes of patients with HF compared with a group of patients with coronary artery disease or hypertension but not HF. On the other hand, Catapano et al<sup><xref ref-type="bibr" rid="bibr61-0884533612444539">61</xref></sup> reported that riboflavin intakes were significantly lower in their cohort of patients with HF compared with their control group (<italic>P</italic> = .009). In addition, most of their patients with HF did not meet the RDA for this vitamin. It should be noted that the HF population in the Catapano et al<sup><xref ref-type="bibr" rid="bibr61-0884533612444539">61</xref></sup> study was considerably older in comparison with that of Arcand et al’s study<sup><xref ref-type="bibr" rid="bibr17-0884533612444539">17</xref></sup> (mean age 73.3 vs 60 years), which could have contributed to the higher prevalence of malnutrition and lower intakes in this group.</p>
<p>Overall, there is insufficient evidence to determine if there is an association between riboflavin deficiency and the risk of HF. However, given the potential impact of riboflavin deficiency on energy production and possibly homocysteine metabolism, future studies are warranted.<sup><xref ref-type="bibr" rid="bibr44-0884533612444539">44</xref>,<xref ref-type="bibr" rid="bibr64-0884533612444539">64</xref></sup></p>
</sec>
<sec id="section5-0884533612444539">
<title>Niacin (Vitamin B<sub>3</sub>)</title>
<p>Niacin, also known as nicotinic acid, nicotinamide, or niacinamide, is required for nicotinamide adenine dinucleotide phosphate (NADP) and nicotinamide adenine dinucleotide (NAD) biosynthesis and therefore acts as a coenzyme in both anabolic (synthesis of fatty acids and cholesterol) and catabolic reactions (ATP production from free energy stores in carbohydrates, fats, and proteins).<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref></sup> Deficiency of niacin is mainly associated with the development of pellagra. Aside from its nutrient-related roles, niacin (in large doses of 2–6 g/d) is used as an antihyperlipidemic agent. The results of several comprehensive reviews on the combination lipid therapy showed that coadministration of niacin together with statin therapy is a more effective method of achieving target lipid levels compared with statin therapy alone; this includes a decrease in low-density lipoprotein (LDL) cholesterol and triglycerides as well as an increase in high-density lipoprotein (HDL) cholesterol.<sup><xref ref-type="bibr" rid="bibr65-0884533612444539">65</xref><xref ref-type="bibr" rid="bibr66-0884533612444539"/><xref ref-type="bibr" rid="bibr67-0884533612444539"/>-<xref ref-type="bibr" rid="bibr68-0884533612444539">68</xref></sup> The preventive effect of nicotinic acid in the formation of LDL is assumed to be through inhibition of triglyceride (TG) lipolysis in adipose tissue and prevention of hepatic TG synthesis.<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref>,<xref ref-type="bibr" rid="bibr69-0884533612444539">69</xref></sup></p>
<p>Niacin was recommended by the 1999 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines as one of the treatment options for post–acute myocardial infarction (AMI) patients with low HDL cholesterol and elevated TG.<sup><xref ref-type="bibr" rid="bibr70-0884533612444539">70</xref></sup> In addition, in a recent review by Bermudez et al,71 niacin treatment was linked to a reduction in heart disease mortality in patients with myocardial infarction. Moreover, low HDL has been suggested as a strong independent risk factor for coronary artery disease.<sup><xref ref-type="bibr" rid="bibr72-0884533612444539">72</xref></sup> However, the findings of recent studies investigating the prevalence of niacin deficiency in patients with HF have shown mixed results. In the previously described study by Catapano et al,<sup><xref ref-type="bibr" rid="bibr61-0884533612444539">61</xref></sup> 69.3% of the HF group had dietary intakes of niacin that were below RDA levels compared with only 29% for controls without HF. The mean dietary intake of niacin was also found to be significantly lower in the HF group compared with that of the controls (<italic>P</italic> &lt; .001). In contrast, the Gorelik et al<sup><xref ref-type="bibr" rid="bibr15-0884533612444539">15</xref></sup> study reported no differences in the dietary intake of niacin between patients with severe HF in comparison with those with moderate HF. Furthermore, the dietary intakes of niacin were above the RDA in both HF and control groups. No study to date has investigated the potential relationship between niacin supplementation and the management of HF. Therefore, overall, there are insufficient data to draw any conclusions regarding relationships between niacin intakes, prevalence of deficiency, and the incidence of HF.</p>
</sec>
<sec id="section6-0884533612444539">
<title>Pantothenic Acid (Vitamin B<sub>5</sub>)</title>
<p>Pantothenic acid or vitamin B<sub>5</sub> is required for the synthesis of coenzyme-A (CoA) and is involved in cellular metabolism.<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref>,<xref ref-type="bibr" rid="bibr44-0884533612444539">44</xref></sup> The adequate intake is between 4 and 7 mg/d (RDA is not defined).<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref></sup> Deficiency of vitamin B<sub>5</sub> is extremely rare, except in severe cases of malnutrition,<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref>,<xref ref-type="bibr" rid="bibr73-0884533612444539">73</xref></sup> and is associated with a burning sensation in the feet, neuritis of arms, fatigue, headache, and weakness. There are no data on either the prevalence of B<sub>5</sub> deficiency in patients with HF or any links to HF management.<sup><xref ref-type="bibr" rid="bibr74-0884533612444539">74</xref></sup> Considering the significance of pantothenic acid in the synthesis of acetyl-CoA, which plays a central role in the Krebs cycle,<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref></sup> and subsequently in cellular energy production, studies defining the prevalence of vitamin B<sub>5</sub> deficiency in this population are warranted.</p>
</sec>
<sec id="section7-0884533612444539">
<title>Vitamin B<sub>6</sub> (Pyridoxine)</title>
<p>Pyridoxine, commonly known as vitamin B<sub>6</sub>, plays a role in the production of red blood cells as well as functioning as a coenzyme in amino acid and carbohydrate metabolism.<sup><xref ref-type="bibr" rid="bibr1-0884533612444539">1</xref>,<xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> Vitamin B<sub>6</sub> deficiency commonly results in neurological problems and anemia.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> However, deficiency can also impair calcium and magnesium metabolism and inhibits the metabolism of homocysteine, which can contribute to hyperhomocysteinemia.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> Because vitamin B<sub>6</sub> is an essential coenzyme in the production of cellular energy, a deficiency of this vitamin may also contribute to the depletion of cellular energy reserves observed in HF.<sup><xref ref-type="bibr" rid="bibr6-0884533612444539">6</xref>,<xref ref-type="bibr" rid="bibr48-0884533612444539">48</xref>,<xref ref-type="bibr" rid="bibr75-0884533612444539">75</xref></sup> Moreover, B<sub>6</sub> deficiency may be exacerbated in patients with HF due to excessive urinary excretion, having limited tissue storage and being dependent on intake.<sup><xref ref-type="bibr" rid="bibr6-0884533612444539">6</xref></sup> In a previously described study by Catapano et al,<sup><xref ref-type="bibr" rid="bibr61-0884533612444539">61</xref></sup> the dietary intake of pyridoxine was found to be significantly reduced in patients with HF compared with patients without HF (<italic>P</italic> &lt; .001). Moreover, the mean dietary intake of pyridoxine was also found to be below the RDA in the HF group. On the contrary, Arcand et al<sup><xref ref-type="bibr" rid="bibr17-0884533612444539">17</xref></sup> did not find any differences in the dietary intake of pyridoxine patients with HF in comparison with controls. It should be noted, however, that the conflicting findings of these studies could be the result of differences in the characteristics of the patient populations studied, the type of diet, and the geographical nutrient distribution of food items. Keith et al<sup><xref ref-type="bibr" rid="bibr6-0884533612444539">6</xref></sup> investigated the prevalence of vitamin B<sub>2</sub> and vitamin B<sub>6</sub> deficiency in a cross section of hospitalized patients with HF. The investigators determined B<sub>6</sub> deficiency by plasma B<sub>6</sub> concentrations, measured as pyridoxal-5′-phosphate, using the radioimmunoassay technique. A modified sqFFQ was also used to assess dietary B<sub>6</sub> intake. The authors reported a 38% prevalence of vitamin B<sub>6</sub> deficiency, which was significantly different from their control group (<italic>P</italic> &lt; .001). Moreover, 68% of patients with HF were found to have evidence of deficiency for at least 1 B vitamin (B<sub>2</sub> or B<sub>6</sub>) in comparison with 42% of controls. No relationship was found between age, HF severity, kidney function, or diuretic usage and vitamin B<sub>6</sub> status. Of interest, patients with moderate to severe left ventricular dysfunction were less likely to be vitamin B<sub>6</sub> deficient. However, patients in the subjective global assessment class A (well nourished) were more likely to be B<sub>6</sub> deficient. Although the use of a B vitamin–containing supplement resulted in approximately a 50% reduction in deficiency rates, the prevalence of B<sub>6</sub> deficiency in HF supplement users did not significantly differ from nonsupplement users. It is therefore likely that B<sub>6</sub> deficiency is not related to worsening HF and is more likely influenced by clinical and nutrition factors other than those associated with vitamin B<sub>1</sub> or B<sub>2</sub>.<sup><xref ref-type="bibr" rid="bibr6-0884533612444539">6</xref></sup> The limited number of studies investigating the singular role B<sub>6</sub> plays in the management of HF suggests that further investigations should be conducted.</p>
</sec>
<sec id="section8-0884533612444539">
<title>Biotin (Vitamin B<sub>7</sub>)</title>
<p>Biotin, also known as vitamin B<sub>7</sub>, acts as a coenzyme in the metabolism of carbohydrates, fat, and protein.<sup><xref ref-type="bibr" rid="bibr76-0884533612444539">76</xref></sup> It also plays a role in gluconeogenesis.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> Intestinal bacteria are capable of producing biotin.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> The adequate intake for biotin for adults is 30 µg per day (no defined RDA).<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> Biotin deficiency is characterized by a loss of hair color, thinning of the hair, scaly red dermatitis, hallucinations, depression, and muscle pain.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> This deficiency is usually found in people consuming an excess of raw egg whites over a period of time as raw egg whites contain a protein that binds biotin and impairs its absorption.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> To our knowledge, no study has yet investigated the potential efficacy of biotin as an adjunct therapy in the management of HF. Limited data exist on the biotin content of foods as well as the role of biotin in various disease states.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref>,<xref ref-type="bibr" rid="bibr76-0884533612444539">76</xref></sup> Because the 4 biotin-dependent carboxylases (pyruvate carboxylase, acetyl-CoA carboxylase, propionyl CoA carboxylase, and B-methylcrotonyl CoA carboxylase) are part of the Krebs cycle and required for gluconeogenesis and fatty acid synthesis, it is possible that reduced available biotin could disrupt gluconeogenesis or fatty acid synthesis,<sup><xref ref-type="bibr" rid="bibr76-0884533612444539">76</xref></sup> which in turn could impair ATP production, resulting in a state of energy deprivation as observed in the failing heart.</p>
</sec>
<sec id="section9-0884533612444539">
<title>Folic Acid (Vitamin B<sub>9</sub>)</title>
<p>Folate or folic acid, also known as pteroylglutamate or pteroylmonoglutamate, functions as a coenzyme tetrahydrofolate (THF) in amino acid metabolism and DNA synthesis. It has been found to enhance endothelium-dependent vasodilatation in a number of vascular diseases such as hypercholesteremia, hypertension, and diabetes mellitus.<sup><xref ref-type="bibr" rid="bibr77-0884533612444539">77</xref><xref ref-type="bibr" rid="bibr78-0884533612444539"/>-<xref ref-type="bibr" rid="bibr79-0884533612444539">79</xref></sup> The mechanism by which folate enhances endothelial function is by interacting directly with endothelium nitric oxide synthase to enhance production of vasoactive substances such as nitric oxide to maintain vascular tone and function.<sup><xref ref-type="bibr" rid="bibr80-0884533612444539">80</xref>,<xref ref-type="bibr" rid="bibr81-0884533612444539">81</xref></sup> Folate deficiency can result in adverse health effects, including megaloblastic, macrocytic anemia.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> Inadequate folic acid intake in the periconceptional period can result in neural tube defects.<sup><xref ref-type="bibr" rid="bibr82-0884533612444539">82</xref>,<xref ref-type="bibr" rid="bibr83-0884533612444539">83</xref></sup> Moreover, folate deficiency in combination with vitamin B<sub>12</sub> deficiency can lead to elevated levels of homocysteine in the blood. <sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> Factors associated with folate deficiency in HF include malabsorption, anorexia, reduced appetite, consumption of folate-lacking foods, and abnormalities in liver function, impairing the storage of active metabolites of folic acid.<sup><xref ref-type="bibr" rid="bibr19-0884533612444539">19</xref></sup></p>
<p>Brady et al<sup><xref ref-type="bibr" rid="bibr19-0884533612444539">19</xref></sup> assessed the frequency of folic acid deficiency in patients with current or a history of HF. The study consisted of 12 participants in total, of whom 10 had current or past HF and the presence of megaloblasts in the bone marrow (suggestive of megaloblastic anemia at the time of the study). The investigators conducted a bone marrow aspiration to determine the presence of megaloblastic anemia. Five of the 10 participants had overt anemia. All participants were using some form of a diuretic. Two had other forms of heart disease and were not receiving diuretics. The study found that all 10 participants with HF had folic acid deficiency, as determined by serum folate, compared with only 2 participants with no evidence of HF. The main limitations of this study are its small sample size as well as the inclusion of patients with comorbidities that complicate the separation of the relationship between folic acid deficiency and HF.</p>
<p>Recent studies have been conducted to investigate the prevalence of micronutrient deficiencies in patients with HF. In the previously described study by Gorelik et al,<sup><xref ref-type="bibr" rid="bibr15-0884533612444539">15</xref></sup> dietary intake of folic acid was found to be below the RDA in both HF and control groups. However, no difference was found in the folic acid intake of patients with HF compared with the controls or between those with moderate vs severe HF symptoms. Factors including the use of a Mediterranean diet, elderly age, or other comorbidities have been suggested to influence dietary intake of folic acid. Similarly, Arcand et al<sup><xref ref-type="bibr" rid="bibr17-0884533612444539">17</xref></sup> found an inadequate dietary intake of folic acid in their patients with HF, but these intake levels were not different from the control group of patients without HF. On the other hand, Catapano et al<sup><xref ref-type="bibr" rid="bibr61-0884533612444539">61</xref></sup> found a significantly reduced dietary intake of folic acid in patients with HF compared with their control group (<italic>P</italic> &lt; .001). This study supports the findings of the Arcand et al<sup><xref ref-type="bibr" rid="bibr17-0884533612444539">17</xref></sup> and Gorelik et al<sup><xref ref-type="bibr" rid="bibr15-0884533612444539">15</xref></sup> studies, which also reported that patients with HF did not meet the RDA for folic acid.<sup><xref ref-type="bibr" rid="bibr61-0884533612444539">61</xref></sup> Given the inadequate levels of dietary intake of folic acid in these studies, further investigations of the role of folic acid deficiency in patients with HF would be important to assess the relevance of supplementation in this population.</p>
<p>A recent study by Makarewicz-Wujec et al<sup><xref ref-type="bibr" rid="bibr84-0884533612444539">84</xref></sup> investigated potential relationships between nutrient intakes of vitamin C, dietary fiber, and folic acid on homocysteine, cytokines, and markers of oxidative stress in patients with HF. Furthermore, they investigated the link between folic acid deficiency as measured by serum folate, the risk of hyperhomocysteinemia, and HF. The study population consisted of 55 patients with HF class I and II who were treated with diuretics and compared these with 55 control patients with hyperlipidemia. Dietary intake was evaluated using a 24-hour recall. The results suggested that patients with HF and hyperhomocysteinemia consumed significantly less folic acid, vitamin C, and dietary fiber in comparison to their control group (<italic>P</italic> &lt; .05). It was also found that the dietary intake of folic acid in patients with HF was below the DRI. This relationship may be related to the influence of diuretics on the hyperexcretion of folic acid. The authors concluded that a low consumption of folic acid accompanied by a high consumption of total fat and cholesterol could contribute to elevated levels of homocysteine, cytokines, and markers of oxidative stress, which may, in turn, exacerbate HF symptoms or progression.</p>
<p>Impairment of endothelium-dependent vasodilatation in patients with HF is common and is attributable to the impaired endothelial release of nitric oxide (NO) and decreased vasodilatation.<sup><xref ref-type="bibr" rid="bibr85-0884533612444539">85</xref></sup> Moreover, increased levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelium NO synthase, have been shown to predict the incidence of adverse outcomes in patients with HF.<sup><xref ref-type="bibr" rid="bibr86-0884533612444539">86</xref>,<xref ref-type="bibr" rid="bibr87-0884533612444539">87</xref></sup> Paul et al<sup><xref ref-type="bibr" rid="bibr88-0884533612444539">88</xref></sup> conducted a mechanistic study to test the hypothesis that 5-methyl-THF (5-MTHF) acutely enhanced endothelial function in patients with HF by NO-dependent mechanisms and to test its effect on ADMA concentrations. The study population consisted of 22 patients with HF and 22 healthy controls. The study protocol included measurements of serum folic acid, homocysteine, ADMA concentrations, arterial wave reflection, and endothelial function. This study did not find any significant effect on endothelium-dependent vasodilatation or endothelium-independent vasodilatation as a result of 5-MTHF infusion. However, it was found that the infusion of 5-MTHF reduced ADMA concentrations. Although this study suggests an acute effect of 5-MTHF in lowering ADMA concentrations, it is difficult to draw any conclusions regarding the impact of this reduction on long-term cardiac function. Further research is warranted to assess the long-term effects of folic acid on endothelial function in the HF population as well as on outcomes.</p>
</sec>
<sec id="section10-0884533612444539">
<title>Vitamin B<sub>12</sub></title>
<p>Vitamin B<sub>12</sub>, known as cobalamin, acts as a coenzyme involved in the formation of blood, nervous system function, and homocysteine metabolism.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> Vitamin B<sub>12</sub> deficiency can lead to anemia.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> Neurological symptoms such as gait disturbances, dementia, insomnia, and impaired bladder and bowel control are also related to vitamin B<sub>12</sub> deficiency.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> There is limited literature on the potential role of vitamin B<sub>12</sub> in the management of patients with HF.</p>
<p>Hepatic congestion may accompany decompensated biventricular HF due to the activation of the neurohormonal system. This activation ultimately results in elevations in systemic venous pressure leading to hepatocellular dysfunction. Zafarullah et al<sup><xref ref-type="bibr" rid="bibr89-0884533612444539">89</xref></sup> proposed a role for vitamin B<sub>12</sub> as a diagnostic marker for the severity of salt and water retention associated with the hepatic congestion found in patients with HF. The authors hypothesized that the hepatic congestion, which contributes to systemic illness found in patients with HF, would be associated with impaired cobalamin uptake. Levels of serum cobalamin in hospitalized patients with biventricular HF (n = 37) were compared with hospitalized patients with left ventricular HF (n = 18) or hospitalized patients without HF (n = 35). Serum cobalamin values were found to be significantly greater in patients with biventricular HF compared with patients with left ventricular HF or those without HF (<italic>P</italic> &lt; .0001). When patients with biventricular HF were treated with intensive medical therapy, serum cobalamin values were reduced by 29%. The group suggested monitoring serum cobalamin levels as a biomarker for expanded intravascular volume in the absence of hepatocyte injury in patients with decompensated biventricular HF. To our knowledge, this is the only study to date showing the potential utility of vitamin B<sub>12</sub> alone in the management of patients with HF. Future studies should further investigate the role of B<sub>12</sub> as a marker of sodium and fluid retention in patients with HF as well as defining any relationships between dietary intake of vitamin B<sub>12</sub> and HF.</p>
</sec>
<sec id="section11-0884533612444539">
<title>Vitamin B<sub>6</sub>, Vitamin B<sub>12</sub>, and Vitamin B<sub>9</sub></title>
<p>Vitamin B<sub>6</sub>, folate, and vitamin B<sub>12</sub> play a role in the metabolism of homocysteine. Folate and vitamin B<sub>12</sub> are required the metabolism of homocysteine to methionine, along with vitamin B<sub>6</sub>, which is required for the conversion of homocysteine to cystathionine.<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref></sup> The intakes of these 3 vitamins are inversely related to plasma tHcy concentrations.<sup><xref ref-type="bibr" rid="bibr90-0884533612444539">90</xref><xref ref-type="bibr" rid="bibr91-0884533612444539"/>-<xref ref-type="bibr" rid="bibr92-0884533612444539">92</xref></sup> As discussed previously, recent data have implicated elevated homocysteine levels as a risk factor of poor prognosis for patients with HF. Factors potentially contributing to elevated homocysteine levels in the HF population include elderly age, impaired renal function, severely impaired ejection fraction, and reduced levels of folate, vitamin B<sub>12</sub>, and vitamin B<sub>6</sub>.<sup><xref ref-type="bibr" rid="bibr32-0884533612444539">32</xref>,<xref ref-type="bibr" rid="bibr34-0884533612444539">34</xref>,<xref ref-type="bibr" rid="bibr93-0884533612444539">93</xref></sup> Supplementation with folic acid, vitamin B<sub>12</sub>, and vitamin B<sub>6</sub> has been shown to normalize or reduce circulating levels of homocysteine, thereby potentially decreasing the risk of heart disease.<sup><xref ref-type="bibr" rid="bibr92-0884533612444539">92</xref>,<xref ref-type="bibr" rid="bibr94-0884533612444539">94</xref><xref ref-type="bibr" rid="bibr93-0884533612444539"/><xref ref-type="bibr" rid="bibr94-0884533612444539"/><xref ref-type="bibr" rid="bibr95-0884533612444539"/><xref ref-type="bibr" rid="bibr96-0884533612444539"/>-<xref ref-type="bibr" rid="bibr97-0884533612444539">97</xref></sup> Limited studies have been conducted to assess the relationship between the clinical symptoms of HF and of B vitamin status or homocysteine concentrations.<sup><xref ref-type="bibr" rid="bibr31-0884533612444539">31</xref></sup></p>
<p>A prospective cohort study assessed the relationship between dietary intakes of folate, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub> and the risk of cardiovascular disease and HF in an Asian population.<sup><xref ref-type="bibr" rid="bibr98-0884533612444539">98</xref></sup> The study consisted of 23,119 men and 35,611 women who had completed a food frequency questionnaire. The authors reported a relationship between lower levels of dietary folate and vitamin B<sub>6</sub> intake and higher mortality rates from HF for men, although no relationship was found for B<sub>12</sub>. This relationship remained even after adjustment for cardiovascular disease risk factors. One hypothesis put forward for the lack of relationship between vitamin B<sub>12</sub> and mortality risk was related to the different mechanisms by which vitamin B<sub>12</sub> may contribute to the functional, biochemical, and clinical parameters of HF outcomes. Sosin et al<sup><xref ref-type="bibr" rid="bibr99-0884533612444539">99</xref></sup> measured the plasma homocysteine, vitamin B<sub>12</sub>, and folate levels in multiethnic patients with HF (n = 112) and compared them with healthy controls (n = 131). Homocysteine levels were found to be significantly higher in patients with HF in comparison with controls (<italic>P</italic> &lt; .001). Furthermore, high levels of plasma folate and vitamin B<sub>12</sub> were associated with lower levels of homocysteine, suggesting a protective effect of these B vitamins. However, the key limitations of this study include the lack of dietary assessment and the acute nature of the study. These limitations make it difficult to draw definite conclusions on the interdependency of B vitamins and homocysteine levels as well as their relation to HF.</p>
<p>A recent study investigated the clinical, functional, and biochemical signs of HF in relation to plasma homocysteine, folate, and vitamin B<sub>12</sub>.<sup><xref ref-type="bibr" rid="bibr33-0884533612444539">33</xref></sup> The study population consisted of 987 ambulatory patients with HF. Blood analysis included measurements of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and serum levels of homocysteine, folate, and vitamin B<sub>12</sub>. Hepatic and renal function was also determined to assess the potential impact of functional impairment on vitamin B<sub>12</sub> and homocysteine levels. No association was found between folate and ejection fraction or folate and NYHA class. NT-proBNP was also not found to be associated with circulating levels of folate. Only a weak negative correlation was found between vitamin B<sub>12</sub> and EF (<italic>P</italic> = .015). On the other hand, a positive correlation was observed between B<sub>12</sub> and NYHA class (<italic>P</italic> &lt; .001). NT-proBNP was found to have a weak correlation with vitamin B<sub>12</sub> (<italic>P</italic> = .004). The authors concluded that the lack of relationship between vitamin B<sub>12</sub>, folate, and HF could be related to the presence of mild hepatic dysfunction in these patients. This hepatic dysfunction could contribute to the release of cobalamin from hepatic cells, resulting in an increase in circulating levels of vitamin B<sub>12</sub> and subsequently affecting the utilization of folate. One of the key limitations of this study includes the lack of dietary assessment data to quantify the intake of B vitamins from food or vitamin supplements.</p>
<p>Limited and conflicting data exist on the role of B vitamins on the relation between homocysteine and HF. To our knowledge, no studies have assessed the role of vitamin B6 together with folate and vitamin B<sub>12</sub> on the relationship between homocysteine and outcomes in HF. Given that B vitamin supplementation is an effective strategy to lower homocysteine, future studies should be focused on linking vitamin supplementation with HF outcomes.</p>
</sec>
</sec>
<sec id="section12-0884533612444539">
<title>Multiple-Nutrient Supplementation Trials</title>
<p>The potential impact of multiple-nutrient treatment therapy on heart function, symptoms, or quality of life in patients with HF remains largely unexplored. Perhaps the most comprehensive investigation in this field was the trial done by Witte et al,<sup><xref ref-type="bibr" rid="bibr14-0884533612444539">14</xref></sup> who investigated the impact of multinutrient supplementation on cardiac function. In this study, 30 elderly patients (mean [SD] age 75.4 [0.7] years) with HF were randomized to receive capsules containing high doses of micronutrients (including vitamins B<sub>1</sub>, B<sub>2</sub>, B<sub>6</sub>, B<sub>9</sub>, and B<sub>12</sub>) or a placebo for 9 months. The primary end point, LVEF, was measured using cardiac magnetic resonance imaging both at baseline and at the end of study. Patients also completed the Euro Quality-of-Life (QoL) HF questionnaire to evaluate NYHA class as well as QoL issues associated with HF. The results revealed a significant improvement in LVEF in patients who received the supplement compared with those who received the placebo (<italic>P</italic> &lt; .05). However, no change in NYHA class between groups was observed. In addition, the QoL score increased significantly in patients taking the supplement (<italic>P</italic> &lt; .02) and decreased in the placebo group (<italic>P</italic> = <italic>NS</italic>). One significant drawback in the design of the study, however, was that dietary intake was not measured. More important, plasma nutrient concentrations were not measured either at baseline or after supplementation. These missing data limit any conclusions that can be drawn on the influence of nutrient supplementation on the cardiac function.</p>
</sec>
<sec id="section13-0884533612444539">
<title>Limitations and Future Projects</title>
<p>Despite therapeutic advances in the management of HF, HF continues to place a significant burden on the individual as well as on the healthcare system. Given the relatively poor long-term prognosis of this population, the role of alternative treatments and preventive strategies becomes increasingly important.<sup><xref ref-type="bibr" rid="bibr13-0884533612444539">13</xref>,<xref ref-type="bibr" rid="bibr101-0884533612444539">101</xref></sup> Emerging evidence supports a link between myocardial dysfunction and impaired cardiac energetics as well as micronutrient deficiencies.<sup><xref ref-type="bibr" rid="bibr13-0884533612444539">13</xref></sup> The links between micronutrient deficiency, dietary intake, and cardiac energetics are poorly understood but offer a potentially exciting avenue for future investigations. Because B vitamins play a role in energy production, it is reasonable to hypothesize that suboptimal nutrient concentrations might contribute to impaired ATP production and subsequently to the progression of HF. A summary of the current studies linking B vitamins with the management of HF can be found in <xref ref-type="table" rid="table2-0884533612444539">Table 2</xref>.</p>
<table-wrap id="table2-0884533612444539" position="float">
<label>Table 2.</label>
<caption>
<p>General Characteristics of B Vitamins<sup><xref ref-type="bibr" rid="bibr21-0884533612444539">21</xref>,<xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref>,<xref ref-type="bibr" rid="bibr44-0884533612444539">44</xref>,<xref ref-type="bibr" rid="bibr51-0884533612444539">51</xref>,<xref ref-type="bibr" rid="bibr52-0884533612444539">52</xref>,<xref ref-type="bibr" rid="bibr64-0884533612444539">64</xref>,<xref ref-type="bibr" rid="bibr100-0884533612444539">100</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0884533612444539" xlink:href="10.1177_0884533612444539-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">B Vitamin</th>
<th align="center">Major Dietary Sources</th>
<th align="center">RDA Range for Adults</th>
<th align="center">Common Deficiency State</th>
<th align="center">Potential Impact of Deficiency on HF</th>
<th align="center">Influence of Supplementation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiamin</td>
<td>Cereals, enriched grains, meat, nuts</td>
<td>1.1–1.2 mg/d</td>
<td>Beriberi</td>
<td>Thiamin deficiency, by limiting the rate of ATP production, might affect myocardial dysfunction</td>
<td>Improvement in LVEF<sup><xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref>,<xref ref-type="bibr" rid="bibr11-0884533612444539">11</xref></sup></td>
</tr>
<tr>
<td>B<sub>1</sub></td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Riboflavin</td>
<td>Milk, dairy, meat, fish, poultry, dark leafy vegetables, whole grain</td>
<td>1.1–1.3 mg/d</td>
<td>Cheilosis, dermatitis, peripheral neuropathy, burning and itching eye</td>
<td>Deficiency may indirectly increase the risk for HF through the following:</td>
<td>No studies retrieved</td>
</tr>
<tr>
<td>B<sub>2</sub></td>
<td/>
<td/>
<td/>
<td>Elevation in tHcy levels (role in tHcy metabolism)</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Energy deprivation (coenzyme role in sugar and protein metabolism)</td>
<td/>
</tr>
<tr>
<td>Niacin</td>
<td>Meat, fish, nuts</td>
<td>14–16 mg/d</td>
<td>Pellagra</td>
<td>Lower levels of HDL, which in turn increases the risk for coronary artery disease, may indirectly influence the risk of HF</td>
<td>No studies retrieved</td>
</tr>
<tr>
<td>B<sub>3</sub></td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Pantothenic acid</td>
<td>Meat, poultry, legumes, whole grains</td>
<td>Not defined</td>
<td>Extremely rare; burning sensation of feet, fatigue, neuritis of arms<sup><xref ref-type="bibr" rid="bibr28-0884533612444539">28</xref>,<xref ref-type="bibr" rid="bibr44-0884533612444539">44</xref></sup></td>
<td>Deficiency may affect the Krebs cycle and ATP production; reduced ATP stores may increase the risk for the development and progression of HF</td>
<td>No studies retrieved</td>
</tr>
<tr>
<td>B<sub>5</sub></td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Pyridoxine</td>
<td>Cereals, organ meats, fish, poultry, starchy vegetables</td>
<td>1.3–1.7 mg/d</td>
<td>Neurological impairments, seizures, anemia, glossitis</td>
<td>Energy deprivation (coenzyme in carbohydrate metabolism), lower levels of tHcy</td>
<td>Limited data<sup><xref ref-type="bibr" rid="bibr14-0884533612444539">14</xref></sup></td>
</tr>
<tr>
<td>B<sub>6</sub></td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Biotin</td>
<td>Liver, soybeans, egg yolk, legumes, nuts, cereals</td>
<td>Not defined</td>
<td>Alopecia, dermatitis, hallucinations, muscle pain</td>
<td>Energy deprivation (coenzyme in carbohydrate and fat metabolism)</td>
<td>No studies retrieved</td>
</tr>
<tr>
<td>B<sub>7</sub></td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Folate</td>
<td>Fortified grains, vegetables, legumes, citrus fruits, liver</td>
<td>400 µg/d</td>
<td>Anemia, fatigue, dyspnea, irritability, difficulty concentrating</td>
<td>Endothelium-dependent vasodilation enhancer, lower levels of tHcy</td>
<td>Limited data<sup><xref ref-type="bibr" rid="bibr14-0884533612444539">14</xref></sup></td>
</tr>
<tr>
<td>B<sub>9</sub></td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Cobalamin</td>
<td>Meat, poultry, fish, shellfish, eggs</td>
<td>2.4 µg/d</td>
<td>Anemia, pale skin, fatigue, dementia, insomnia</td>
<td>Lower levels of tHcy, potential marker of sodium and fluid retention</td>
<td>Limited data<sup><xref ref-type="bibr" rid="bibr14-0884533612444539">14</xref></sup></td>
</tr>
<tr>
<td>B<sub>12</sub></td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0884533612444539">
<p>ATP, adenosine triphosphate; HDL, high-density lipoprotein; HF, heart failure; LVEF, left ventricular ejection fraction; RDA, recommended dietary allowance; tHcy, total homocysteine.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Results from a handful of smaller studies suggest that correcting micronutrient deficiencies might benefit cardiac function.<sup><xref ref-type="bibr" rid="bibr10-0884533612444539">10</xref>,<xref ref-type="bibr" rid="bibr11-0884533612444539">11</xref>,<xref ref-type="bibr" rid="bibr63-0884533612444539">63</xref></sup> However, there are still substantial gaps within the literature in this area. Most of the trials mentioned thus far have been limited by their small sample sizes and insufficient or missing control groups.<sup><xref ref-type="bibr" rid="bibr7-0884533612444539">7</xref>,<xref ref-type="bibr" rid="bibr14-0884533612444539">14</xref>,<xref ref-type="bibr" rid="bibr89-0884533612444539">89</xref></sup> Some of these studies included individuals with comorbidities, which makes interpretation of the prevalence of B vitamin deficiency data or data on the impact of B vitamin supplementation on functional, clinical, or biochemical parameters of HF challenging.<sup><xref ref-type="bibr" rid="bibr7-0884533612444539">7</xref></sup> In addition, some of these supplementation trials were not randomized or did not study key outcomes vital to the functional or clinical improvement of HF.<sup><xref ref-type="bibr" rid="bibr11-0884533612444539">11</xref>,<xref ref-type="bibr" rid="bibr98-0884533612444539">98</xref></sup> Furthermore, only some studies mentioned the use of dietary analysis, whereby most did not employ any sort of method for evaluating the diet of their patient population.<sup><xref ref-type="bibr" rid="bibr6-0884533612444539">6</xref>,<xref ref-type="bibr" rid="bibr33-0884533612444539">33</xref>,<xref ref-type="bibr" rid="bibr88-0884533612444539">88</xref>,<xref ref-type="bibr" rid="bibr99-0884533612444539">99</xref></sup> Moreover, several factors other than dietary intake are likely to contribute to variations in serum levels of nutrients. Some of these factors specific to patients with HF include increased resting energy expenditure, disease severity, the dose and duration of medications, increased catabolism, and increased cardiac work. Therefore, it is not known whether dietary deficiency affects serum levels and, if so, what the underlying mechanisms are. Furthermore, because the dietary intake of many of these vitamins was not found to be significantly different compared with the intake of the control groups, there is also a chance that the dietary intake of HF patients is not necessarily different from that of other chronically ill elderly groups. In fact, the study by Gorelik et al<sup><xref ref-type="bibr" rid="bibr15-0884533612444539">15</xref></sup> suggests that HF per se may not be solely responsible for the low intake level and that older age, other chronic conditions, and a population-related dietary culture have contributed to the observed lower intake level. Finally, there have been wide variations in dietary assessment techniques used to evaluate the level of B vitamin intake. These inconsistencies in the dietary assessment methodologies further complicate comparisons between studies.</p>
<p>The interaction of B vitamins with other nutrients or drugs is also an important avenue for future investigations considering that patients with HF are usually prescribed a combination of drugs and are generally considered at increased risk of malnutrition. Studies assessing the impact of single or multiple diuretic therapy in inducing urinary losses of B vitamins are needed to clarify our understanding of the impact of these drugs both on B vitamin losses as well as on biochemical status. Furthermore, studies conducted across the continuum of HF development will help in identifying critical points at which the patient may be at the highest risk of nutrient deficiency. Patients might benefit from one-on-one counseling with dietitians, and thus, a registered dietitian should also be considered as part of the multidisciplinary team. Additional studies defining the impact of long-term B vitamin supplementation on HF outcomes would assist in guiding the clinical management of this population. Last, although pantothenic acid and biotin, like thiamin, have defined roles in energy production, they have received limited attention in terms of the influence that they might have in the management of HF. It has been argued that the majority of studies that have been conducted using singular vitamin supplementation in patients with HF contribute to the inconsistencies observed in the existing literature.<sup><xref ref-type="bibr" rid="bibr13-0884533612444539">13</xref>,<xref ref-type="bibr" rid="bibr101-0884533612444539">101</xref></sup> Considering that patients with HF may not be deficient in just one micronutrient and that nutrients work synergistically in biochemical processes, trials addressing multiple micronutrient deficiencies may have a larger impact on outcomes in comparison with single-nutrient interventions.<sup><xref ref-type="bibr" rid="bibr13-0884533612444539">13</xref></sup> One such trial has been conducted and has demonstrated a benefit associated with the supplementation of multiple nutrients in patients with HF.<sup><xref ref-type="bibr" rid="bibr14-0884533612444539">14</xref></sup> However, there is a need for larger, randomized trials in this area. On the other hand, it can be argued that until we understand the role and function of individual micronutrients at different stages of HF, we may not be able to assess the impact of multiple-nutrient supplementation or even determine which nutrients should be provided in combination. We propose that further research on the impact of both singular and multiple B vitamin supplementation on the functional, clinical, and biochemical parameters of HF is required.</p>
</sec>
<sec id="section14-0884533612444539">
<title>Conclusion</title>
<p>Nutrient requirements as well as the impact of targeted nutrition therapy on heart function in patients with HF remain largely unexplored. Current dietary reference intakes are established for healthy populations, leading to questions regarding their applicability in disease states such as HF. Although some evidence supports an increased prevalence of B vitamin deficiency in patients with HF, the literature is inconsistent and incomplete. Furthermore, there is a paucity of well-powered studies investigating the relationships between nutrition status, nutrient intake, and outcomes, including heart function, in both ambulatory and hospitalized patients. Larger trials that define the prevalence of individual B vitamin deficiency followed by randomized controlled intervention studies are required to assess safety and efficacy of B vitamin supplementation on outcomes in patients with HF.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
<fn fn-type="other">
<p>Drs Azizi-Namini and Ahmed are co–first authors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533612444539">
<label>1.</label>
<citation citation-type="web">
<collab>The Heart and Stroke Foundation</collab>. <article-title>Statistics</article-title>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm">http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm</ext-link>. Updated 2011</comment>.</citation>
</ref>
<ref id="bibr2-0884533612444539">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>LM</given-names></name>
<name><surname>Roubenoff</surname><given-names>R.</given-names></name>
</person-group> <article-title>The nutrition implications of cardiac cachexia</article-title>. <source>Nutr Re</source>v. <year>1994</year>;<volume>52</volume>(<issue>10</issue>):<fpage>340</fpage>-<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr3-0884533612444539">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anker</surname><given-names>SD</given-names></name>
<name><surname>Steinborn</surname><given-names>W</given-names></name>
<name><surname>Strassburg</surname><given-names>S.</given-names></name>
</person-group> <article-title>Cardiac cachexia</article-title>. <source>Ann Med</source>. <year>2004</year>;<volume>36</volume>(<issue>7</issue>):<fpage>518</fpage>-<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr4-0884533612444539">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilkinson</surname><given-names>TJ</given-names></name>
<name><surname>Hanger</surname><given-names>HC</given-names></name>
<name><surname>Elmslie</surname><given-names>J</given-names></name>
<name><surname>George</surname><given-names>PM</given-names></name>
<name><surname>Sainsbury</surname><given-names>R.</given-names></name>
</person-group> <article-title>The response to treatment of subclinical thiamine deficiency in the elderly</article-title>. <source>Am J Clin Nutr</source>. <year>1997</year>;<volume>66</volume>(<issue>4</issue>):<fpage>925</fpage>-<lpage>928</lpage>.</citation>
</ref>
<ref id="bibr5-0884533612444539">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanninen</surname><given-names>SA</given-names></name>
<name><surname>Darling</surname><given-names>PB</given-names></name>
<name><surname>Sole</surname><given-names>MJ</given-names></name>
<name><surname>Barr</surname><given-names>A</given-names></name>
<name><surname>Keith</surname><given-names>ME.</given-names></name>
</person-group> <article-title>The prevalence of thiamin deficiency in hospitalized patients with congestive heart failure</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>47</volume>(<issue>2</issue>):<fpage>354</fpage>-<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr6-0884533612444539">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keith</surname><given-names>ME</given-names></name>
<name><surname>Walsh</surname><given-names>NA</given-names></name>
<name><surname>Darling</surname><given-names>PB</given-names></name><etal/>
</person-group>. <article-title>B-vitamin deficiency in hospitalized patients with heart failure</article-title>. <source>J Am Diet Assoc</source>. <year>2009</year>;<volume>109</volume>(<issue>8</issue>):<fpage>1406</fpage>-<lpage>1410</lpage>.</citation>
</ref>
<ref id="bibr7-0884533612444539">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brody</surname><given-names>JI</given-names></name>
<name><surname>Soltys</surname><given-names>HD</given-names></name>
<name><surname>Zinsser</surname><given-names>HF.</given-names></name>
</person-group> <article-title>Folic acid deficiency in congestive heart failure</article-title>. <source>Br Heart J</source>. <year>1969</year>;<volume>31</volume>(<issue>6</issue>):<fpage>741</fpage>-<lpage>745</lpage>.</citation>
</ref>
<ref id="bibr8-0884533612444539">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Havivi</surname><given-names>E</given-names></name>
<name><surname>Bar On</surname><given-names>H</given-names></name>
<name><surname>Reshef</surname><given-names>A</given-names></name>
<name><surname>Stein</surname><given-names>P</given-names></name>
<name><surname>Raz</surname><given-names>I</given-names></name>
</person-group>. <article-title>Vitamins and trace metals status in non insulin dependent diabetes mellitus</article-title>. <source>Int J Vitam Nutr Re</source>s. <year>1991</year>;<volume>61</volume>(<issue>4</issue>):<fpage>328</fpage>-<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr9-0884533612444539">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hunt</surname><given-names>SA</given-names></name>
<name><surname>Abraham</surname><given-names>WT</given-names></name>
<name><surname>Chin</surname><given-names>MH</given-names></name><etal/>
</person-group>. <article-title>2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>119</volume>(<issue>14</issue>):<fpage>e391</fpage>-<lpage>e479</lpage>.</citation>
</ref>
<ref id="bibr10-0884533612444539">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seligmann</surname><given-names>H</given-names></name>
<name><surname>Halkin</surname><given-names>H</given-names></name>
<name><surname>Rauchfleisch</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study</article-title>. <source>Am J Med</source>. <year>1991</year>;<volume>91</volume>(<issue>2</issue>):<fpage>151</fpage>-<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr11-0884533612444539">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimon</surname><given-names>I</given-names></name>
<name><surname>Almog</surname><given-names>S</given-names></name>
<name><surname>Vered</surname><given-names>Z</given-names></name><etal/>
</person-group>. <article-title>Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy</article-title>. <source>Am J Med</source>. <year>1995</year>;<volume>98</volume>(<issue>5</issue>):<fpage>485</fpage>-<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr12-0884533612444539">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zenuk</surname><given-names>C</given-names></name>
<name><surname>Healey</surname><given-names>J</given-names></name>
<name><surname>Donnelly</surname><given-names>J</given-names></name>
<name><surname>Vaillancourt</surname><given-names>R</given-names></name>
<name><surname>Almalki</surname><given-names>Y</given-names></name>
<name><surname>Smith</surname><given-names>S</given-names></name>
</person-group>. <article-title>Thiamine deficiency in congestive heart failure patients receiving long term furosemide therapy</article-title>. <source>Can J Clin Pharmacol</source>. <year>2003</year>;<volume>10</volume>(<issue>4</issue>):<fpage>184</fpage>-<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr13-0884533612444539">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soukoulis</surname><given-names>V</given-names></name>
<name><surname>Dihu</surname><given-names>JB</given-names></name>
<name><surname>Sole</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Micronutrient deficiencies an unmet need in heart failure</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>(<issue>18</issue>):<fpage>1660</fpage>-<lpage>1673</lpage>.</citation>
</ref>
<ref id="bibr14-0884533612444539">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Witte</surname><given-names>KK</given-names></name>
<name><surname>Nikitin</surname><given-names>NP</given-names></name>
<name><surname>Parker</surname><given-names>AC</given-names></name><etal/>
</person-group>. <article-title>The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure</article-title>. <source>Eur Heart J</source>. <year>2005</year>;<volume>26</volume>(<issue>21</issue>):<fpage>2238</fpage>-<lpage>2244</lpage>.</citation>
</ref>
<ref id="bibr15-0884533612444539">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorelik</surname><given-names>O</given-names></name>
<name><surname>Almoznino-Sarafian</surname><given-names>D</given-names></name>
<name><surname>Feder</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>Dietary intake of various nutrients in older patients with congestive heart failure</article-title>. <source>Cardiology</source>. <year>2003</year>;<volume>99</volume>(<issue>4</issue>):<fpage>177</fpage>-<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr16-0884533612444539">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemon</surname><given-names>SC</given-names></name>
<name><surname>Olendzki</surname><given-names>B</given-names></name>
<name><surname>Magner</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>The dietary quality of persons with heart failure in NHANES 1999-2006</article-title>. <source>J Gen Intern Med</source>. <year>2010</year>;<volume>25</volume>(<issue>2</issue>):<fpage>135</fpage>-<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr17-0884533612444539">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arcand</surname><given-names>J</given-names></name>
<name><surname>Floras</surname><given-names>V</given-names></name>
<name><surname>Ahmed</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Nutritional inadequacies in patients with stable heart failure</article-title>. <source>J Am Diet Assoc</source>. <year>2009</year>;<volume>109</volume>(<issue>11</issue>):<fpage>1909</fpage>-<lpage>1913</lpage>.</citation>
</ref>
<ref id="bibr18-0884533612444539">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kwok</surname><given-names>T</given-names></name>
<name><surname>Falconer-Smith</surname><given-names>JF</given-names></name>
<name><surname>Potter</surname><given-names>JF</given-names></name>
<name><surname>Ives</surname><given-names>DR.</given-names></name>
</person-group> <article-title>Thiamine status of elderly patients with cardiac failure</article-title>. <source>Age Ageing</source>. <year>1992</year>;<volume>21</volume>(<issue>1</issue>):<fpage>67</fpage>-<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr19-0884533612444539">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brady</surname><given-names>JA</given-names></name>
<name><surname>Rock</surname><given-names>CL</given-names></name>
<name><surname>Horneffer</surname><given-names>MR.</given-names></name>
</person-group> <article-title>Thiamin status, diuretic medications, and the management of congestive heart failure</article-title>. <source>J Am Diet Assoc</source>. <year>1995</year>;<volume>95</volume>(<issue>5</issue>):<fpage>541</fpage>-<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr20-0884533612444539">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abou-Hashem</surname><given-names>RM</given-names></name>
<name><surname>Maamoun</surname><given-names>MM</given-names></name>
<name><surname>Hamza</surname><given-names>SA</given-names></name>
<name><surname>Fahmy</surname><given-names>HM</given-names></name>
<name><surname>Mortagy</surname><given-names>AK.</given-names></name>
</person-group> <article-title>Thiamine level in hospitalized elderly Egyptian patients with congestive heart failure and left ventricular systolic dysfunction</article-title>. <source>J Am Geriatr Soc</source>. <year>2009</year>;<volume>57</volume>(<issue>11</issue>):<fpage>2165</fpage>-<lpage>2166</lpage>.</citation>
</ref>
<ref id="bibr21-0884533612444539">
<label>21.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Gropper</surname><given-names>SAS</given-names></name>
<name><surname>Smith</surname><given-names>JL</given-names></name>
<name><surname>Groff</surname><given-names>JL</given-names></name>
</person-group>. <source>Advanced Nutrition and Human Metabolism</source>. <edition>4th ed.</edition> <publisher-loc>Belmont, CA</publisher-loc>: <publisher-name>Thomson/Wadsworth</publisher-name>; <year>2005</year>.</citation>
</ref>
<ref id="bibr22-0884533612444539">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Connell</surname><given-names>JB.</given-names></name>
</person-group> <article-title>The economic burden of heart failure</article-title>. <source>Clin Cardiol</source>. <year>2000</year>;<volume>23</volume>(<issue>3</issue>)(<supplement>suppl</supplement>):<fpage>III6</fpage>-<lpage>III10</lpage>.</citation>
</ref>
<ref id="bibr23-0884533612444539">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gheorghiade</surname><given-names>M</given-names></name>
<name><surname>Adams</surname><given-names>KF</given-names></name>
<name><surname>Cleland</surname><given-names>JG</given-names></name><etal/>
</person-group>. <article-title>Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group</article-title>. <source>Am Heart J</source>. <year>2009</year>;<volume>157</volume>(<issue>6</issue>):<fpage>957</fpage>-<lpage>970</lpage>.</citation>
</ref>
<ref id="bibr24-0884533612444539">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehra</surname><given-names>MR</given-names></name>
<name><surname>Uber</surname><given-names>PA</given-names></name>
<name><surname>Francis</surname><given-names>GS.</given-names></name>
</person-group> <article-title>Heart failure therapy at a crossroad: are there limits to the neurohormonal model?</article-title> <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>41</volume>(<issue>9</issue>):<fpage>1606</fpage>-<lpage>1610</lpage>.</citation>
</ref>
<ref id="bibr25-0884533612444539">
<label>25.</label>
<citation citation-type="book">
<collab>World Health Organization (WHO)</collab>. <source>Cardiovascular Diseases (CVDs)</source>. <comment>Fact sheet No. 317</comment>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>; <month>September</month> <year>2011</year>.</citation>
</ref>
<ref id="bibr26-0884533612444539">
<label>26.</label>
<citation citation-type="journal">
<collab>WRITING GROUP MEMBERS</collab>, <person-group person-group-type="author">
<name><surname>Lloyd-Jones</surname><given-names>D</given-names></name>
<name><surname>Adams</surname><given-names>RJ</given-names></name><etal/>
</person-group>. <article-title>Heart disease and stroke statistics—2010 update: a report from the American Heart Association</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>121</volume>(<issue>7</issue>):<fpage>e46</fpage>-<lpage>e215</lpage>.</citation>
</ref>
<ref id="bibr27-0884533612444539">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Swedberg</surname><given-names>K</given-names></name>
<name><surname>Cleland</surname><given-names>J</given-names></name>
<name><surname>Dargie</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology</article-title>. <source>Eur Heart J</source>. <year>2005</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1115</fpage>-<lpage>1140</lpage>.</citation>
</ref>
<ref id="bibr28-0884533612444539">
<label>28.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Shils</surname><given-names>ME</given-names></name>
<name><surname>Shike</surname><given-names>M.</given-names></name>
</person-group> <source>Modern Nutrition in Health and Disease</source>. <edition>10th ed.</edition> <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr29-0884533612444539">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Packer</surname><given-names>M</given-names></name>
<name><surname>Miller</surname><given-names>AB.</given-names></name>
</person-group> <article-title>Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure</article-title>. <source>Am J Cardiol</source>. <year>1999</year>;<volume>84</volume>(4A):1L-2L.</citation>
</ref>
<ref id="bibr30-0884533612444539">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname><given-names>KK</given-names></name>
<name><surname>Pinsky</surname><given-names>JL</given-names></name>
<name><surname>Kannel</surname><given-names>WB</given-names></name>
<name><surname>Levy</surname><given-names>D.</given-names></name>
</person-group> <article-title>The epidemiology of heart failure: the Framigham Study</article-title>. <source>J Am Coll Cardiol</source>. <year>1993</year>;<volume>22</volume>(4)(<supplement>suppl A</supplement>): 6A-13A.</citation>
</ref>
<ref id="bibr31-0884533612444539">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herrmann</surname><given-names>M</given-names></name>
<name><surname>Taban-Shomal</surname><given-names>O</given-names></name>
<name><surname>Hubner</surname><given-names>U</given-names></name>
<name><surname>Bohm</surname><given-names>M</given-names></name>
<name><surname>Herrmann</surname><given-names>W.</given-names></name>
</person-group> <article-title>A review of homocysteine and heart failure</article-title>. <source>Eur J Heart Fail</source>. <year>2006</year>;<volume>8</volume>(<issue>6</issue>):<fpage>571</fpage>-<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr32-0884533612444539">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vasan</surname><given-names>RS</given-names></name>
<name><surname>Beiser</surname><given-names>A</given-names></name>
<name><surname>D’Agostino</surname><given-names>RB</given-names></name><etal/>
</person-group>. <article-title>Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>289</volume>(<issue>10</issue>):<fpage>1251</fpage>-<lpage>1257</lpage>.</citation>
</ref>
<ref id="bibr33-0884533612444539">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herrmann</surname><given-names>M</given-names></name>
<name><surname>Muller</surname><given-names>S</given-names></name>
<name><surname>Kindermann</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>Plasma B vitamins and their relation to the severity of chronic heart failure</article-title>. <source>Am J Clin Nutr</source>. <year>2007</year>;<volume>85</volume>(<issue>1</issue>):<fpage>117</fpage>-<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr34-0884533612444539">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naruszewicz</surname><given-names>M</given-names></name>
<name><surname>Jankowska</surname><given-names>EA</given-names></name>
<name><surname>Zymlinski</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Hyperhomocysteinemia in patients with symptomatic chronic heart failure: prevalence and prognostic importance—pilot study</article-title>. <source>Atherosclerosis</source>. <year>2007</year>;<volume>194</volume>(<issue>2</issue>):<fpage>408</fpage>-<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr35-0884533612444539">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>RT.</given-names></name>
</person-group> <article-title>Matrix metalloproteinase inhibition and the prevention of heart failure</article-title>. <source>Trends Cardiovasc Med</source>. <year>2001</year>;<volume>11</volume>(<issue>5</issue>):<fpage>202</fpage>-<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr36-0884533612444539">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stanger</surname><given-names>O</given-names></name>
<name><surname>Weger</surname><given-names>M.</given-names></name>
</person-group> <article-title>Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium</article-title>. <source>Clin Chem Lab Med</source>. <year>2003</year>;<volume>41</volume>(<issue>11</issue>):<fpage>1444</fpage>-<lpage>1454</lpage>.</citation>
</ref>
<ref id="bibr37-0884533612444539">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silver</surname><given-names>MA.</given-names></name>
</person-group> <article-title>Dietary research in heart failure: beyond the salt shaker</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>42</volume>(<issue>7</issue>):<fpage>1224</fpage>-<lpage>1225</lpage>.</citation>
</ref>
<ref id="bibr38-0884533612444539">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hill</surname><given-names>GL.</given-names></name>
<name><surname>Jonathan</surname><given-names>E.</given-names></name>
</person-group> <article-title>Rhoads lecture. Body composition research: implications for the practice of clinical nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1992</year>;<volume>16</volume>(<issue>3</issue>):<fpage>197</fpage>-<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr39-0884533612444539">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lourenco</surname><given-names>BH</given-names></name>
<name><surname>Vieira</surname><given-names>LP</given-names></name>
<name><surname>Macedo</surname><given-names>A</given-names></name>
<name><surname>Nakasato</surname><given-names>M</given-names></name>
<name><surname>Marucci Mde</surname><given-names>F</given-names></name>
<name><surname>Bocchi</surname><given-names>EA.</given-names></name>
</person-group> <article-title>Nutritional status and adequacy of energy and nutrient intakes among heart failure patients</article-title>. <source>Arq Bras Cardiol</source>. <year>2009</year>;<volume>93</volume>(<issue>5</issue>):<fpage>541</fpage>-<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr40-0884533612444539">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Obisesan</surname><given-names>TO</given-names></name>
<name><surname>Toth</surname><given-names>MJ</given-names></name>
<name><surname>Donaldson</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Energy expenditure and symptom severity in men with heart failure</article-title>. <source>Am J Cardiol</source>. <year>1996</year>;<volume>77</volume>(<issue>14</issue>):<fpage>1250</fpage>-<lpage>1252</lpage>.</citation>
</ref>
<ref id="bibr41-0884533612444539">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poehlman</surname><given-names>ET</given-names></name>
<name><surname>Scheffers</surname><given-names>J</given-names></name>
<name><surname>Gottlieb</surname><given-names>SS</given-names></name>
<name><surname>Fisher</surname><given-names>ML</given-names></name>
<name><surname>Vaitekevicius</surname><given-names>P.</given-names></name>
</person-group> <article-title>Increased resting metabolic rate in patients with congestive heart failure</article-title>. <source>Ann Intern Med</source>. <year>1994</year>;<volume>121</volume>(<issue>11</issue>):<fpage>860</fpage>-<lpage>862</lpage>.</citation>
</ref>
<ref id="bibr42-0884533612444539">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bourdel-Marchasson</surname><given-names>I</given-names></name>
<name><surname>Emeriau</surname><given-names>JP.</given-names></name>
</person-group> <article-title>Nutritional strategy in the management of heart failure in adults</article-title>. <source>Am J Cardiovasc Drugs</source>. <year>2001</year>;<volume>1</volume>(<issue>5</issue>):<fpage>363</fpage>-<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr43-0884533612444539">
<label>43.</label>
<citation citation-type="web">
<collab>Health Canada</collab>. <article-title>Dietary reference intakes</article-title>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.hc-sc.gc.ca/fn-an/nutrition/reference/cons_info-guide_cons-eng.php">http://www.hc-sc.gc.ca/fn-an/nutrition/reference/cons_info-guide_cons-eng.php</ext-link>. Updated November 29, 2010</comment>. <access-date>Accessed November 30, 2011</access-date>.</citation>
</ref>
<ref id="bibr44-0884533612444539">
<label>44.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hark</surname><given-names>L</given-names></name>
<name><surname>Morrison</surname><given-names>G</given-names></name>
</person-group>. <source>Medical Nutrition and Disease</source>. <publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Blackwell Science</publisher-name>; <volume>1996</volume>:<fpage>3</fpage>-<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr45-0884533612444539">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dunn</surname><given-names>SP</given-names></name>
<name><surname>Bleske</surname><given-names>B</given-names></name>
<name><surname>Dorsch</surname><given-names>M</given-names></name>
<name><surname>Macaulay</surname><given-names>T</given-names></name>
<name><surname>Van Tassell</surname><given-names>B</given-names></name>
<name><surname>Vardeny</surname><given-names>O.</given-names></name>
</person-group> <article-title>Nutrition and heart failure: impact of drug therapies and management strategies</article-title>. <source>Nutr Clin Pract</source>. <year>2009</year>;<volume>24</volume>(<issue>1</issue>):<fpage>60</fpage>-<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr46-0884533612444539">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allard</surname><given-names>ML</given-names></name>
<name><surname>Jeejeebhoy</surname><given-names>KN</given-names></name>
<name><surname>Sole</surname><given-names>MJ.</given-names></name>
</person-group> <article-title>The management of conditioned nutritional requirements in heart failure</article-title>. <source>Heart Fail Rev</source>. <year>2006</year>;<volume>11</volume>(<issue>1</issue>):<fpage>75</fpage>-<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr47-0884533612444539">
<label>47.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Jeejeebhoy</surname><given-names>KN</given-names></name>
<name><surname>Kinney</surname><given-names>JM.</given-names></name>
</person-group> <source>Nutrition and Metabolism in Patient Care</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Saunders</publisher-name>; <year>1988</year>.</citation>
</ref>
<ref id="bibr48-0884533612444539">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neubauer</surname><given-names>S</given-names></name>
<name><surname>Horn</surname><given-names>M</given-names></name>
<name><surname>Cramer</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy</article-title>. <source>Circulation</source>. <year>1997</year>;<volume>96</volume>(<issue>7</issue>):<fpage>2190</fpage>-<lpage>2196</lpage>.</citation>
</ref>
<ref id="bibr49-0884533612444539">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ingwall</surname><given-names>JS</given-names></name>
<name><surname>Atkinson</surname><given-names>DE</given-names></name>
<name><surname>Clarke</surname><given-names>K</given-names></name>
<name><surname>Fetters</surname><given-names>JK.</given-names></name>
</person-group> <article-title>Energetic correlates of cardiac failure: changes in the creatine kinase system in the failing myocardium</article-title>. <source>Eur Heart J</source>. <year>1990</year>;<volume>11</volume>(<supplement>suppl B</supplement>):<fpage>108</fpage>-<lpage>115</lpage>.</citation>
</ref>
<ref id="bibr50-0884533612444539">
<label>50.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Azizi Namini</surname><given-names>P.</given-names></name>
</person-group> <source>The Prevalence of Thiamin Deficiency in Ambulatory Patients With Heart Failure</source> [<comment>master’s thesis</comment>]. <publisher-loc>Toronto, Canada</publisher-loc>: <publisher-name>University of Toronto</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr51-0884533612444539">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sauberlich</surname><given-names>HE.</given-names></name>
</person-group> <article-title>Implications of nutritional status on human biochemistry, physiology, and health</article-title>. <source>Clin Biochem</source>. <year>1984</year>;<volume>17</volume>(<issue>2</issue>):<fpage>132</fpage>-<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr52-0884533612444539">
<label>52.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Guyton</surname><given-names>AC</given-names></name>
<name><surname>Hall</surname><given-names>JE.</given-names></name>
</person-group> <source>Textbook of Medical Physiology</source>. <edition>11th ed.</edition> <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Elsevier Saunders</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr53-0884533612444539">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Keeffe</surname><given-names>ST.</given-names></name>
</person-group> <article-title>Thiamine deficiency in elderly people</article-title>. <source>Age Ageing</source>. <year>2000</year>;<volume>29</volume>(<issue>2</issue>):<fpage>99</fpage>-<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr54-0884533612444539">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pepersack</surname><given-names>T</given-names></name>
<name><surname>Garbusinski</surname><given-names>J</given-names></name>
<name><surname>Robberecht</surname><given-names>J</given-names></name>
<name><surname>Beyer</surname><given-names>I</given-names></name>
<name><surname>Willems</surname><given-names>D</given-names></name>
<name><surname>Fuss</surname><given-names>M.</given-names></name>
</person-group> <article-title>Clinical relevance of thiamine status amongst hospitalized elderly patients</article-title>. <source>Gerontology</source>. <year>1999</year>;<volume>45</volume>(<issue>2</issue>):<fpage>96</fpage>-<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr55-0884533612444539">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemoine</surname><given-names>A</given-names></name>
<name><surname>Le Devehat</surname><given-names>C</given-names></name>
<name><surname>Codaccioni</surname><given-names>JL</given-names></name>
<name><surname>Monges</surname><given-names>A</given-names></name>
<name><surname>Bermond</surname><given-names>P</given-names></name>
<name><surname>Salkeld</surname><given-names>RM.</given-names></name>
</person-group> <article-title>Vitamin B1, B2, B6, and C status in hospital inpatients</article-title>. <source>Am J Clin Nutr</source>. <year>1980</year>;<volume>33</volume>(<issue>12</issue>):<fpage>2595</fpage>-<lpage>2600</lpage>.</citation>
</ref>
<ref id="bibr56-0884533612444539">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lubetsky</surname><given-names>A</given-names></name>
<name><surname>Winaver</surname><given-names>J</given-names></name>
<name><surname>Seligmann</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Urinary thiamine excretion in the rat: effects of furosemide, other diuretics, and volume load</article-title>. <source>J Lab Clin Med</source>. <year>1999</year>;<volume>134</volume>(<issue>3</issue>):<fpage>232</fpage>-<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr57-0884533612444539">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pfitzenmeyer</surname><given-names>P</given-names></name>
<name><surname>Guilland</surname><given-names>JC</given-names></name>
<name><surname>d’Athis</surname><given-names>P</given-names></name>
<name><surname>Petit-Marnier</surname><given-names>C</given-names></name>
<name><surname>Gaudet</surname><given-names>M.</given-names></name>
</person-group> <article-title>Thiamine status of elderly patients with cardiac failure including the effects of supplementation</article-title>. <source>Int J Vitam Nutr Res</source>. <year>1994</year>;<volume>64</volume>(<issue>2</issue>):<fpage>113</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr58-0884533612444539">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yue</surname><given-names>QY</given-names></name>
<name><surname>Beermann</surname><given-names>B</given-names></name>
<name><surname>Lindstrom</surname><given-names>B</given-names></name>
<name><surname>Nyquist</surname><given-names>O.</given-names></name>
</person-group> <article-title>No difference in blood thiamine diphosphate levels between Swedish Caucasian patients with congestive heart failure treated with furosemide and patients without heart failure</article-title>. <source>J Intern Med</source>. <year>1997</year>;<volume>242</volume>(<issue>6</issue>):<fpage>491</fpage>-<lpage>495</lpage>.</citation>
</ref>
<ref id="bibr59-0884533612444539">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levy</surname><given-names>WC</given-names></name>
<name><surname>Soine</surname><given-names>LA</given-names></name>
<name><surname>Huth</surname><given-names>MM</given-names></name>
<name><surname>Fishbein</surname><given-names>DP.</given-names></name>
</person-group> <article-title>Thiamine deficiency in congestive heart failure</article-title>. <source>Am J Med</source>. <year>1992</year>;<volume>93</volume>(<issue>6</issue>):<fpage>705</fpage>-<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr60-0884533612444539">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wooley</surname><given-names>JA.</given-names></name>
</person-group> <article-title>Characteristics of thiamin and its relevance to the management of heart failure</article-title>. <source>Nutr Clin Pract</source>. <year>2008</year>;<volume>23</volume>(<issue>5</issue>):<fpage>487</fpage>-<lpage>493</lpage>.</citation>
</ref>
<ref id="bibr61-0884533612444539">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Catapano</surname><given-names>G</given-names></name>
<name><surname>Pedone</surname><given-names>C</given-names></name>
<name><surname>Nunziata</surname><given-names>E</given-names></name>
<name><surname>Zizzo</surname><given-names>A</given-names></name>
<name><surname>Passantino</surname><given-names>A</given-names></name>
<name><surname>Incalzi</surname><given-names>RA.</given-names></name>
</person-group> <article-title>Nutrient intake and serum cytokine pattern in elderly people with heart failure</article-title>. <source>Eur J Heart Fail</source>. <year>2008</year>;<volume>10</volume>(<issue>4</issue>):<fpage>428</fpage>-<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr62-0884533612444539">
<label>62.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Coulston</surname><given-names>AM</given-names></name>
<name><surname>Boushey</surname><given-names>CJ</given-names></name>
</person-group>, eds. <source>Nutrition in the Prevention and Treatment of Disease</source>. <edition>2nd ed.</edition> <publisher-loc>New York</publisher-loc>: <publisher-name>Academic Press</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr63-0884533612444539">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freye</surname><given-names>E</given-names></name>
<name><surname>Hartung</surname><given-names>E.</given-names></name>
</person-group> <article-title>The potential use of thiamine in patients with cardiac insufficiency</article-title>. <source>Acta Vitaminol Enzymol</source>. <year>1982</year>;<volume>4</volume>(<issue>4</issue>):<fpage>285</fpage>-<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr64-0884533612444539">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Powers</surname><given-names>HJ.</given-names></name>
</person-group> <article-title>Riboflavin (vitamin B-2) and health</article-title>. <source>Am J Clin Nutr</source>. <year>2003</year>;<volume>77</volume>(<issue>6</issue>):<fpage>1352</fpage>-<lpage>1360</lpage>.</citation>
</ref>
<ref id="bibr65-0884533612444539">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deedwania</surname><given-names>PC</given-names></name>
<name><surname>Hunninghake</surname><given-names>DB</given-names></name>
<name><surname>Bays</surname><given-names>H.</given-names></name>
</person-group> <article-title>Effects of lipid altering treatment in diabetes mellitus and the metabolic syndrome</article-title>. <source>Am J Cardiol</source>. <year>2004</year>;<volume>93</volume>(<supplement>suppl</supplement>):18C-26C.</citation>
</ref>
<ref id="bibr66-0884533612444539">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vasudevan</surname><given-names>AR</given-names></name>
<name><surname>Jones</surname><given-names>PH.</given-names></name>
</person-group> <article-title>Effective use of combination lipid therapy</article-title>. <source>Curr Atheroscler Rep</source>. <year>2006</year>;<volume>8</volume>(<issue>1</issue>):<fpage>76</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr67-0884533612444539">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cziraky</surname><given-names>MJ</given-names></name>
<name><surname>Watson</surname><given-names>KE</given-names></name>
<name><surname>Talbert</surname><given-names>RL.</given-names></name>
</person-group> <article-title>Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting</article-title>. <source>J Manag Care Pharm</source>. <year>2008</year>;<volume>14</volume>(<issue>8</issue>)(<supplement>suppl</supplement>):<fpage>S3</fpage>-<lpage>S28</lpage>; <comment>quiz S30-S31</comment>.</citation>
</ref>
<ref id="bibr68-0884533612444539">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Denke</surname><given-names>MA.</given-names></name>
</person-group> <article-title>Coadministration of multidrug therapy to achieve lipid goals</article-title>. <source>J Am Osteopath Assoc</source>. <year>2004</year>;<volume>104</volume>(9)(<supplement>suppl 7</supplement>):<fpage>S17</fpage>-<lpage>S22</lpage>.</citation>
</ref>
<ref id="bibr69-0884533612444539">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ganji</surname><given-names>SH</given-names></name>
<name><surname>Kamanna</surname><given-names>VS</given-names></name>
<name><surname>Kashyap</surname><given-names>ML.</given-names></name>
</person-group> <article-title>Niacin and cholesterol: role in cardiovascular disease [review]</article-title>. <source>J Nutr Biochem</source>. <year>2003</year>;<volume>14</volume>(<issue>6</issue>):<fpage>298</fpage>-<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr70-0884533612444539">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spinler</surname><given-names>SA</given-names></name>
<name><surname>Hilleman</surname><given-names>DE</given-names></name>
<name><surname>Cheng</surname><given-names>JW</given-names></name><etal/>
</person-group>. <article-title>New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines</article-title>. <source>Ann Pharmacother</source>. <year>2001</year>;<volume>35</volume>(<issue>5</issue>):<fpage>589</fpage>-<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr71-0884533612444539">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bermudez</surname><given-names>V</given-names></name>
<name><surname>Cano</surname><given-names>R</given-names></name>
<name><surname>Cano</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Pharmacologic management of isolated low high-density lipoprotein syndrome</article-title>. <source>Am J Ther</source>. <year>2008</year>;<volume>15</volume>(<issue>4</issue>):<fpage>377</fpage>-<lpage>388</lpage>.</citation>
</ref>
<ref id="bibr72-0884533612444539">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toth</surname><given-names>PP.</given-names></name>
</person-group> <article-title>High-density lipoprotein and cardiovascular risk</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>(<issue>15</issue>):<fpage>1809</fpage>-<lpage>1812</lpage>.</citation>
</ref>
<ref id="bibr73-0884533612444539">
<label>73.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Molnar</surname><given-names>JA.</given-names></name>
</person-group> <source>Nutrition and Wound Healing</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>Taylor &amp; Francis</publisher-name>; <year>2007</year>.</citation>
</ref>
<ref id="bibr74-0884533612444539">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tahiliani</surname><given-names>AG</given-names></name>
<name><surname>Beinlich</surname><given-names>CJ.</given-names></name>
</person-group> <article-title>Pantothenic acid in health and disease</article-title>. <source>Vitam Horm</source>. <year>1991</year>;<volume>46</volume>:<fpage>165</fpage>-<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr75-0884533612444539">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neubauer</surname><given-names>S.</given-names></name>
</person-group> <article-title>The failing heart—an engine out of fuel</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>356</volume>(<issue>11</issue>):<fpage>1140</fpage>-<lpage>1151</lpage>.</citation>
</ref>
<ref id="bibr76-0884533612444539">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pacheco-Alvarez</surname><given-names>D</given-names></name>
<name><surname>Solorzano-Vargas</surname><given-names>RS</given-names></name>
<name><surname>Del Rio</surname><given-names>AL.</given-names></name>
</person-group> <article-title>Biotin in metabolism and its relationship to human disease</article-title>. <source>Arch Med Res</source>. <year>2002</year>;<volume>33</volume>(<issue>5</issue>):<fpage>439</fpage>-<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr77-0884533612444539">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mangoni</surname><given-names>AA</given-names></name>
<name><surname>Sherwood</surname><given-names>RA</given-names></name>
<name><surname>Asonganyi</surname><given-names>B</given-names></name>
<name><surname>Swift</surname><given-names>CG</given-names></name>
<name><surname>Thomas</surname><given-names>S</given-names></name>
<name><surname>Jackson</surname><given-names>SH.</given-names></name>
</person-group> <article-title>Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes</article-title>. <source>Am J Hypertens</source>. <year>2005</year>;<volume>18</volume>(2, pt 1):<fpage>220</fpage>-<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr78-0884533612444539">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Etten</surname><given-names>RW</given-names></name>
<name><surname>de Koning</surname><given-names>EJ</given-names></name>
<name><surname>Verhaar</surname><given-names>MC</given-names></name>
<name><surname>Gaillard</surname><given-names>CA</given-names></name>
<name><surname>Rabelink</surname><given-names>TJ.</given-names></name>
</person-group> <article-title>Impaired NO-dependent vasodilation in patients with type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate</article-title>. <source>Diabetologia</source>. <year>2002</year>;<volume>45</volume>(<issue>7</issue>):<fpage>1004</fpage>-<lpage>1010</lpage>.</citation>
</ref>
<ref id="bibr79-0884533612444539">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doshi</surname><given-names>SN</given-names></name>
<name><surname>McDowell</surname><given-names>IF</given-names></name>
<name><surname>Moat</surname><given-names>SJ</given-names></name><etal/>
</person-group>. <article-title>Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>105</volume>(<issue>1</issue>):<fpage>22</fpage>-<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr80-0884533612444539">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyndman</surname><given-names>ME</given-names></name>
<name><surname>Verma</surname><given-names>S</given-names></name>
<name><surname>Rosenfeld</surname><given-names>RJ</given-names></name>
<name><surname>Anderson</surname><given-names>TJ</given-names></name>
<name><surname>Parsons</surname><given-names>HG.</given-names></name>
</person-group> <article-title>Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2002</year>;<volume>282</volume>(<issue>6</issue>):<fpage>H2167</fpage>-<lpage>H2172</lpage>.</citation>
</ref>
<ref id="bibr81-0884533612444539">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Antoniades</surname><given-names>C</given-names></name>
<name><surname>Shirodaria</surname><given-names>C</given-names></name>
<name><surname>Warrick</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>114</volume>(<issue>11</issue>):<fpage>1193</fpage>-<lpage>1201</lpage>.</citation>
</ref>
<ref id="bibr82-0884533612444539">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milunsky</surname><given-names>A</given-names></name>
<name><surname>Jick</surname><given-names>H</given-names></name>
<name><surname>Jick</surname><given-names>SS</given-names></name><etal/>
</person-group>. <article-title>Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects</article-title>. <source>JAMA</source>. <year>1989</year>;<volume>262</volume>(<issue>20</issue>):<fpage>2847</fpage>-<lpage>2852</lpage>.</citation>
</ref>
<ref id="bibr83-0884533612444539">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shaw</surname><given-names>GM</given-names></name>
<name><surname>Schaffer</surname><given-names>D</given-names></name>
<name><surname>Velie</surname><given-names>EM</given-names></name>
<name><surname>Morland</surname><given-names>K</given-names></name>
<name><surname>Harris</surname><given-names>JA.</given-names></name>
</person-group> <article-title>Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects</article-title>. <source>Epidemiology</source>. <year>1995</year>;<volume>6</volume>(<issue>3</issue>):<fpage>219</fpage>-<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr84-0884533612444539">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Makarewicz-Wujec</surname><given-names>M</given-names></name>
<name><surname>Kozlowska-Wojciechowska</surname><given-names>M.</given-names></name>
</person-group> <article-title>Nutrient intake and serum level of gamma-glutamyltransferase, MCP-1 and homocysteine in early stages of heart failure</article-title>. <source>Clin Nutr</source>. <year>2011</year>;<volume>30</volume>(<issue>1</issue>):<fpage>73</fpage>-<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr85-0884533612444539">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abassi</surname><given-names>ZA</given-names></name>
<name><surname>Gurbanov</surname><given-names>K</given-names></name>
<name><surname>Mulroney</surname><given-names>SE</given-names></name><etal/>
</person-group>. <article-title>Impaired nitric oxide–mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II</article-title>. <source>Circulation</source>. <year>1997</year>;<volume>96</volume>(<issue>10</issue>):<fpage>3655</fpage>-<lpage>3664</lpage>.</citation>
</ref>
<ref id="bibr86-0884533612444539">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Usui</surname><given-names>M</given-names></name>
<name><surname>Matsuoka</surname><given-names>H</given-names></name>
<name><surname>Miyazaki</surname><given-names>H</given-names></name>
<name><surname>Ueda</surname><given-names>S</given-names></name>
<name><surname>Okuda</surname><given-names>S</given-names></name>
<name><surname>Imaizumi</surname><given-names>T.</given-names></name>
</person-group> <article-title>Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure</article-title>. <source>Life Sci</source>. <year>1998</year>;<volume>62</volume>(<issue>26</issue>):<fpage>2425</fpage>-<lpage>2430</lpage>.</citation>
</ref>
<ref id="bibr87-0884533612444539">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duckelmann</surname><given-names>C</given-names></name>
<name><surname>Mittermayer</surname><given-names>F</given-names></name>
<name><surname>Haider</surname><given-names>DG</given-names></name>
<name><surname>Altenberger</surname><given-names>J</given-names></name>
<name><surname>Eichinger</surname><given-names>J</given-names></name>
<name><surname>Wolzt</surname><given-names>M.</given-names></name>
</person-group> <article-title>Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2007</year>;<volume>27</volume>(<issue>9</issue>):<fpage>2037</fpage>-<lpage>2042</lpage>.</citation>
</ref>
<ref id="bibr88-0884533612444539">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paul</surname><given-names>B</given-names></name>
<name><surname>Whiting</surname><given-names>MJ</given-names></name>
<name><surname>De Pasquale</surname><given-names>CG</given-names></name>
<name><surname>Mangoni</surname><given-names>AA.</given-names></name>
</person-group> <article-title>Acute effects of 5-methyltetrahydrofolate on endothelial function and asymmetric dimethylarginine in patients with chronic heart failure</article-title>. <source>Nutr Metab Cardiovasc Dis</source>. <year>2010</year>;<volume>20</volume>(<issue>5</issue>):<fpage>341</fpage>-<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr89-0884533612444539">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zafarullah</surname><given-names>H</given-names></name>
<name><surname>Shahbaz</surname><given-names>AU</given-names></name>
<name><surname>Alturkmani</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Elevated serum cobalamin in patients with decompensated biventricular failure</article-title>. <source>Am J Med Sci</source>. <year>2008</year>;<volume>336</volume>(<issue>5</issue>):<fpage>383</fpage>-<lpage>388</lpage>.</citation>
</ref>
<ref id="bibr90-0884533612444539">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Refsum</surname><given-names>H</given-names></name>
<name><surname>Ueland</surname><given-names>PM</given-names></name>
<name><surname>Nygard</surname><given-names>O</given-names></name>
<name><surname>Vollset</surname><given-names>SE.</given-names></name>
</person-group> <article-title>Homocysteine and cardiovascular disease</article-title>. <source>Annu Rev Med</source>. <year>1998</year>;<volume>49</volume>:<fpage>31</fpage>-<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr91-0884533612444539">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimakawa</surname><given-names>T</given-names></name>
<name><surname>Nieto</surname><given-names>FJ</given-names></name>
<name><surname>Malinow</surname><given-names>MR</given-names></name>
<name><surname>Chambless</surname><given-names>LE</given-names></name>
<name><surname>Schreiner</surname><given-names>PJ</given-names></name>
<name><surname>Szklo</surname><given-names>M.</given-names></name>
</person-group> <article-title>Vitamin intake: a possible determinant of plasma homocyst(e)ine among middle-aged adults</article-title>. <source>Ann Epidemiol</source>. <year>1997</year>;<volume>7</volume>(<issue>4</issue>):<fpage>285</fpage>-<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr92-0884533612444539">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boushey</surname><given-names>CJ</given-names></name>
<name><surname>Beresford</surname><given-names>SA</given-names></name>
<name><surname>Omenn</surname><given-names>GS</given-names></name>
<name><surname>Motulsky</surname><given-names>AG.</given-names></name>
</person-group> <article-title>A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes</article-title>. <source>JAMA</source>. <year>1995</year>;<volume>274</volume>(<issue>13</issue>):<fpage>1049</fpage>-<lpage>1057</lpage>.</citation>
</ref>
<ref id="bibr93-0884533612444539">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herrmann</surname><given-names>M</given-names></name>
<name><surname>Kindermann</surname><given-names>I</given-names></name>
<name><surname>Muller</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Relationship of plasma homocysteine with the severity of chronic heart failure</article-title>. <source>Clin Chem</source>. <year>2005</year>;<volume>51</volume>(<issue>8</issue>):<fpage>1512</fpage>-<lpage>1515</lpage>.</citation>
</ref>
<ref id="bibr94-0884533612444539">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ubbink</surname><given-names>JB</given-names></name>
<name><surname>Vermaak</surname><given-names>WJ</given-names></name>
<name><surname>van der Merwe</surname><given-names>A</given-names></name>
<name><surname>Becker</surname><given-names>PJ.</given-names></name>
</person-group> <article-title>Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia</article-title>. <source>Am J Clin Nutr</source>. <year>1993</year>;<volume>57</volume>(<issue>1</issue>):<fpage>47</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr95-0884533612444539">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ubbink</surname><given-names>JB</given-names></name>
<name><surname>Vermaak</surname><given-names>WJ</given-names></name>
<name><surname>van der Merwe</surname><given-names>A</given-names></name>
<name><surname>Becker</surname><given-names>PJ</given-names></name>
<name><surname>Delport</surname><given-names>R</given-names></name>
<name><surname>Potgieter</surname><given-names>HC.</given-names></name>
</person-group> <article-title>Vitamin requirements for the treatment of hyperhomocysteinemia in humans</article-title>. <source>J Nutr</source>. <year>1994</year>;<volume>124</volume>(<issue>10</issue>):<fpage>1927</fpage>-<lpage>1933</lpage>.</citation>
</ref>
<ref id="bibr96-0884533612444539">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sato</surname><given-names>Y</given-names></name>
<name><surname>Honda</surname><given-names>Y</given-names></name>
<name><surname>Iwamoto</surname><given-names>J</given-names></name>
<name><surname>Kanoko</surname><given-names>T</given-names></name>
<name><surname>Satoh</surname><given-names>K.</given-names></name>
</person-group> <article-title>Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>293</volume>(<issue>9</issue>):<fpage>1082</fpage>-<lpage>1088</lpage>.</citation>
</ref>
<ref id="bibr97-0884533612444539">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clarke</surname><given-names>R</given-names></name>
<name><surname>Armitage</surname><given-names>J.</given-names></name>
</person-group> <article-title>Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements</article-title>. <source>Semin Thromb Hemost</source>. <year>2000</year>;<volume>26</volume>(<issue>3</issue>):<fpage>341</fpage>-<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr98-0884533612444539">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cui</surname><given-names>R</given-names></name>
<name><surname>Iso</surname><given-names>H</given-names></name>
<name><surname>Date</surname><given-names>C</given-names></name>
<name><surname>Kikuchi</surname><given-names>S</given-names></name>
<name><surname>Tamakoshi</surname><given-names>A</given-names></name>
</person-group>; <collab>Japan Collaborative Cohort Study Group</collab>. <article-title>Dietary folate and vitamin B6 and B12 intake in relation to mortality from cardiovascular diseases: Japan collaborative cohort study</article-title>. <source>Stroke</source>. <year>2010</year>;<volume>41</volume>(<issue>6</issue>):<fpage>1285</fpage>-<lpage>1289</lpage>.</citation>
</ref>
<ref id="bibr99-0884533612444539">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sosin</surname><given-names>MD</given-names></name>
<name><surname>Patel</surname><given-names>JV</given-names></name>
<name><surname>Bhatia</surname><given-names>GS</given-names></name>
<name><surname>Hughes</surname><given-names>EA</given-names></name>
<name><surname>Davis</surname><given-names>RC</given-names></name>
<name><surname>Lip</surname><given-names>GY.</given-names></name>
</person-group> <article-title>Effects of white European, African Caribbean and South Asian ethnicity on homocysteine levels in patients with systolic heart failure</article-title>. <source>Int J Cardiol</source>. <year>2008</year>;<volume>129</volume>(<issue>1</issue>):<fpage>69</fpage>-<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr100-0884533612444539">
<label>100.</label>
<citation citation-type="web">
<article-title>Dietary reference intakes</article-title>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.hc-sc.gc.ca/fn-an/alt_formats/hpfb-dgpsa/pdf/nutrition/dri_tables-eng.pdf">http://www.hc-sc.gc.ca/fn-an/alt_formats/hpfb-dgpsa/pdf/nutrition/dri_tables-eng.pdf</ext-link></comment>, <access-date>accessed April 10, 2012</access-date>.</citation>
</ref>
<ref id="bibr101-0884533612444539">
<label>101.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarma</surname><given-names>S</given-names></name>
<name><surname>Gheorghiade</surname><given-names>M.</given-names></name>
</person-group> <article-title>Nutritional assessment and support of the patient with acute heart failure</article-title>. <source>Curr Opin Crit Care</source>. <year>2010</year>;<volume>16</volume>(<issue>5</issue>):<fpage>413</fpage>-<lpage>418</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>